H1N1 Swine Flu Virus,
Vacccines and the X-FILES. ! Gripe H1N1
Virus, Vacunas
y los Expedientes Secretos X !.
DATA-MEDICOS
DERMAGIC/EXPRESS 19-(208)
10 Septiembre 2.017 10 September 2.017
EDITORIAL ENGLISH
===================
Hello friend of
the network, after analyzing the TRAGEDY worldwide
with the GARDASIL
AND CERVARIX VACCINES created
to prevent HPV, HUMAN PAPILLOMA VIRUS,
which has caused numerous DEATHS
WORLDWIDE, and GREAT
SIDE EFFECTS, DISABILITY OF MANY
PEOPLE, and the latest LAWSUIT in
COLOMBIA on August 4, 2017 against
laboratory MERCK SHARP AND DHOME AND THE
GARDASIL for collateral damage and death
to more than 700 COLOMBIAN
GIRLS, I
decided to launch the 3 publications
OVER THE
H1N1 SWINE FLU that carried out
in the year 2.009 about he SUPPOSED
PANDEMIA by this influenza was spreading
all over the world.
In these 3 publications it is narrated ALL
THE HISTORY that was behind
this FLU AH1N1 whose ultimate goal we
can deduce it in the following:
1.) DECREASE THE WORLD POPULATION.
2.) CREATE
VACCINES AGAINST THE FLU AND OBLIGATE
THE POPULATION TO TAKE IT.
3.) GENERATE
MONEY FOR THE SALE OF THESE VACCINES.
This caused worldwide a SOCIAL
STRUGGLE against compulsory
vaccination, as it was proven that it
was a MORE INVENTORY to sell VACCINES whose
side effects could leave you DISABLED or KILL you
DERMAGIC EXPRESS who had
more than one DECADE publishing on
DERMATOLOGICAL AND NON-DERMATOLOGICAL
subjects, denouncing BAD medicines,
advising the population, DECIDED by
then TO REALIZE THESE
THREE PUBLICATIONS that today
I am going to place you with changing
SOME WORDS, with the UNIQUE aim of
providing BIBLIOGRAPHIC REFERENCES to
all those who struggle today against BAD
VACCINES, those that instead
of healing you lead to DEATH or PHYSICAL
INCAPACITATION.
For that time I decided to take a break
which lasted from 2.009 to 2.017, in
which I return once more to the same DERMAGIC
EXPRESS' MACHINE, perhaps a little
quiet, but always telling TRUTHS about
MEDICATIONS, DISEASES AND VACCINES.
Always respect the LABORATORIES,
because as I have always said THE
MISSION of them is to CREATE
AND INVENT MEDICINES to heal
the diseases of humanity. But I tell you
that some of them DO NOT RESPECT YOUR
OPINION and when you say and test
SCIENTIFICALLY THAT A MEDICINE OR
VACCINE IS BAD AND SHOULD BE REMOVED
FROM THE MARKET, they attack
you without compassion, trying to
disqualify your opinions.
For this reason DERMAGIC EXPRESS always
launches a BIBLIOGRAPHIC REVIEW does
with the technological supports,
SCIENTIFIC PUBLICATIONS, WEB PAGES WITH
PRESTIGE AND TRUE
TESTIMONIALS, I always
inquire strongly before publishing an
article.
In the case of LAWSUIT IN COLOMBIA against
MERCK SHARP & DHOME AND THE GARDASIL
VACCINE, this is a fight of DAVID
AGAINST GOLIAT, you are
facing a MONSTER that will try to
disqualify you to continue SELLING the
VACCINES, or simply pay the 160 MILLION
DOLLARS and will continue in the same.
MERCK SHARP & DHOME has as a whole a
very GOOD MEDICINES like
FINASTERIDE (PROSCAR AND PROPECIA),
contraceptives, etc, but in the case
of GARDASIL unfortunately
the invention was NOT GOOD and in
my opinion they should be withdrawn
from the market both GARDASIL as CERVARIX of
the laboratory GLAXOSMITHKLINE (GSK),
who comes from a bad experience with the
vaccine against LYME DISEASE, called
LYMErix, which was already
withdrawn from the market in the year
2.002.
Here I leave you the first of the three
(3) ORIGINAL publications that SPREAD
AWARENESS ALL OVER THE PLANET about
what happened with the A1H1N1 FLU, but
hard the comments, but adjusted to the
reality of that time, here you can read,
and in this publication I leave the BIBLIOGRAPHY
support OF THE REVIEW:
1.) H1N1 INFLUENZE, THE RESIDENT EVIL
I, IN THE ROUTE TO THE VIROLOGIC WAR !!!
By the way
The VACCCINE
GARDASIL 9 (VALENTE), contains ALUMINUM
adjuvant and today 9 of
September 2.017 get in the social MEDIUM network
the following post:
French scientists sound the alarm
about aluminum in vaccines -
crickets from media and health
authorities: (Reference
19)
Where it is widely spoken of the
damage caused by ALUMINIUM
in the VACCINES and the
silence of the MEDIA of the CDC and
others.
Let me tell you that this is not new,
and I added other BIBLIOGRAPHIC
REFERENCES on the subject of VACCINES
AND ALUMINUM, (ref.
19,45,46) and OTHERS ADJUVANTS, (THIMEROSAL
OTHERS ref, 40,41,42,43,44,
48,49,50,52) and if you think
that VACCINES
ARE TOTALLY SAFE, I
recommend you read ALL THESE
BIBLIOGRAPHIC REFERENCES
Greetings to all
Dr. Jose Lapenta.
EDITORIAL ESPAÑOL
===================
Hola amigo de la
red, después de analizar de analizar muy
bien la TRAGEDIA a nivel mundial
con las VACUNAS
GARDASIL Y CERVARIX creadas
para prevenir el VPH, VIRUS DEL PAPILOMA
HUMANO, el cual lo que ha provocado son
numerosas MUERTES EN
TODO EL MUNDO, y GRANDES EFECTOS
SECUNDARIOS, INCAPACITACION DE
MUCHAS PERSONAS, y la ultima demanda
en COLOMBIA día 4 de agosto 2.017 contra
el laboratorio MERCK SHARP AND DHOME Y
EL GARDASIL por daños colaterales y
muerte a más DE 700 NIÑAS
COLOMBIANAS, decidí sacar a
flote las 3 publicaciones SOBRE
LA INFLUENZA H1N1 que realice
en los años 2.009 la SUPUESTA PANDEMIA
por esta gripe estaba diseminándose por
todo el mundo.
En estas 3 publicaciones se narra TODA
LA HISTORIA que estuvo detrás
de esta GRIPE AH1N1 cuyo oblativo final
lo podemos deducir en lo sigiuiente:
1.) DISMINUIR LA POBLACION MUNDIAL.
2.) CREAR
VACUNAS CONTRA ELLA Y OBLIGAR A LA
POBLACION A COLOCARSELAS.
3.) GENERAR
DINERO POR LA VENTA DE ESTAS VACUNAS.
Ello provoco a nivel mundial una LUCHA
SOCIAL en contra de la VACUNACION
OBLIGATORIA, al comprobarse que se
trataba de un INVENTO MAS para vender
VACUNAS cuyos efectos secundarios podían
dejarte INCAPACITADO o MATARTE.
DERMAGIC EXPRESS quien tenía más de
una DECADA publicando sobre temas
DERMATOLOGICOS Y NO DERMATOLOGICOS,
denunciando medicinas MALAS, aconsejando
a la población, DECIDIO para aquel
entonces REALIZAR ESTAS TRES
PUBLICACIONES que hoy te voy a
colocar cambiando pocas LETRAS, con el
único objetivo de proporcionar
REFERENCIAS BIBLIOGRAFICAS a todos
aquellos que luchan hoy día contra las MALAS
VACUNAS, aquellas que en lugar de
sanarte te llevan a la MUERTE
o INCAPACITACION FISICA.
Para esa época DECIDI tomarme un
descanso el cual duro DESDE 2.009 AL
2.017, en que retorne una vez más con la MISMA
MAQUINARIA, quizá un poco más
calmado, pero siempre diciendo VERDADES
sobre MEDICAMENTOS, ENFERMEDADES Y
VACUNAS.
Siempre respete a los LABORATORIOS,
porque como he dicho siempre LA MISION
de ellos es CREAR
E INVENTAR MEDICINAS para
sanar las enfermedades de la humanidad.
Pero les cuento que algunos de ellos NO
RESPETAN TU OPINION y cuando dices y
pruebas CIENTIFICAMENTE QUE UNA
MEDICINA O VACUNA ES MALA Y DEBE SER
RETIRADA DEL MERCADO, te
atacan sin compasión, tratando de
descalificar tus opiniones.
Por este motivo el DERMAGIC EXPRESS
siempre que lanza una REVISION
BIBLIOGRAFICA lo hace con los soportes
tecnológicos, léase PUBLICACIONES
CIENTIFICAS, PAGINAS WEB DE PRESTIGIO Y TESTIMONIALES
VERDADEROS, siempre indago
fuertemente antes de publicar un
artículo.
En al caso DE LA DEMANDA EN COLOMBIA contra
MERCK SHARP & DHOME Y LA VACUNA
GARDASIL, se trata de una
lucha de DAVID
CONTRA GOLIAT, te estás
enfrentando a un MOUNSTRUO que va a
tratar de descalificarte para seguir
VENDIENDO SUS VACUNAS, o simplemente
pagara LOS 160 MILLONES DE DOLARES y
seguirá en lo mismo.
MERCK SHARP & DHOME tiene como todo
laboratorio UNAS MUY BUENAS MEDICINAS como
el FINASTERIDE (PROSCAR Y PROPECIA),
anticonceptivos y otras, Pero en el caso
de GARDASIL lamentablemente
el invento NO FUE BUENO y en mi
opinión deberían ser retiradas del
mercados TANTO GARDASIL como CERVARIX del
laboratorio GLAXOSMITHKLINE (GSK),
quien viene de una mala experiencia con
la vacuna contra la ENFERMEDAD DE LYME,
denominada LYMErix,
LA CUAL ya fue retirada del mercado en
él año 2.002.
Aquí les dejo la primera de las (3)
publicaciones ORIGINALES
QUE SEMBRARON CONCIENCIA EN TODO EL
PLANETA sobre lo que ocurrió
con la GRIPE A1H1N1, bien duros los
comentarios, pero ajustados a la
realidad de aquella época, aquí las
puedes leer, y en esta publicacion te
dejo el soporte
BIBLIOGRAFICO DE LA REVISION.
Por cierto La VACUNA
GARDASIL 9 (VALENTE), contiende
de adyuvante
ALUMINIO y hoy 9 de
Septiempre 2.017 me consigo en la red
Social MEDIUM el siguiente post:
French scientists sound the alarm about
aluminum in vaccines — crickets from
media and health authorities: (Referencia
19)
Donde se habla extensamente del daño
causado por el
ALUMINIO en las VACUNAS y el
silencio de los MEDIOS DE COMUNICACION
el CDC y otros.
Dejenme decirles que esto no es nuevo
alli les añadi otras REFERENCIAS
BIBLIOGRAFICAS sobre el tema de las VACUNAS
Y EL ALUMINIO, (ref.
19,45,46) y OTROS ADYUVANTES (TIMEROSAL, OTROS ref.
40 41,42,43,44 48,49,50,52), y
si piensas que las VACUNAS
SON TOTALMENTE SEGURAS, te
recomiendo que leas TODAS ESTAS
RFERENCIAS BIBLIOGRAFICAS.
Saludos a todos
=======================================================================
REFERENCIAS BIBLIOGRAFICAS/
BIBLIOGRAPHICAL REFERENCES
=======================================================================
=======================================================================
1.) MedImmune patentó el virus AH1N1 en 2008
2.) Medimmune H1N1 Swine Flu Virus - PATENT
- 2008, Startling New Evidence That The 'Swine
Flu' Pandemic IsMan-Made
3.) Roche Receives FDA Approval Of TAMIFLU™,
First Pill To Treat The Most Common Strains
Of Influenza (A&B)
4.) "Prepandemic" immunization for novel
influenza viruses, "swine flu" vaccine,
Guillain-Barré syndrome, and the detection
of rare severe adverse events.
5.) Vacuna contra gripe H1N1 está bajo
vigilancia por efectos secundarios
6.) Vacuna influenza H1N1 genera problema a
fabricantes: FDA de Estados Unidos
7.) El Tamiflu, Donald Rumsfeld y el negocio
del miedo
8.) The Tamiflu / Rumsfeld Connection
9.) Donald Rumsfeld's controversial links to
drug company behind Tamiflu
10.) China anuncia primera vacuna contra
Gripe Porcina H1N1
11.) Baxter, los virus de la gripe
extraviados y el plasma sanguíneo
contaminado.
12.) OMS a juicio por Bioterrorismo por la
Gripe Porcina
13.) Farmacéuticas, las ganadoras frente a
la influenza
14.) Big Pharma: Baxter Files Swine Flu
Vaccine Patent a Year Ahead of Outbreak
15.) AstraZeneca compra la estadounidense
Medimmune por mas de 11.000 millones de
euros
16.) Dos mutaciones hacen letal al H5N1
17.) VACUNA H1N1: Múltiples efectos
secundarios en Suecia por Pandemrix (GSK) y
en Suiza entran grandes dudas
18.) Fort Detrick Inventory Turns Up 9,220
More Vials of Pathogens
19.) French scientists sound the alarm about
aluminum in vaccines — crickets from media
and health authorities:
20.) Influenza vaccination and Guillain
Barre syndrome small star, filled.
21.) Guillain-Barré syndrome following
influenza vaccination.
22.) Clinical implications of endotoxin
concentrations in vaccines.
23.) Guillain-Barré syndrome after influenza
vaccination in adults: a population-based
study.24.) Novel Pandemic Influenza A(H1N1)
Viruses Are Potently Inhibited by DAS181, a
Sialidase Fusion Protein
25.)A one year followup of chronic arthritis
following rubella and hepatitis B
vaccination based upon analysis of the
Vaccine Adverse Events Reporting System (VAERS)
database.
26.) Investigation of the temporal
association of Guillain-Barre syndrome with
influenza vaccine and influenzalike illness
using the United Kingdom General Practice
Research Database.
27.) Update: Guillain-Barré syndrome among
recipients of Menactra meningococcal
conjugate vaccine--United States, June 2005-September
2006.
28.) Guillain-Barre syndrome following
vaccination in the National Influenza
Immunization
Program, United States, 1976--1977.
29.) Adverse events after inactivated
influenza vaccination among children less
than 2 years of age: analysis of reports
from the vaccine adverse event reporting
system, 1990-2003.
30.)Vaccines and Guillain-Barré syndrome.
31.) potential signal of Bell's palsy after
parenteral inactivated influenza vaccines:
reports to the Vaccine Adverse Event
Reporting System (VAERS)--United States,
1991-2001.
32.) Adverse events reported following live,
cold-adapted, intranasal influenza vaccine.
33.) Monitoring the safety of annual and
pandemic influenza vaccines: lessons from
the US experience.
34.) Are toxic biometals destroying your
children's future?
35.) Surveillance for safety after
immunization: Vaccine Adverse Event
Reporting System
(VAERS)--United States, 1991-2001.
36.) Media coverage of the measles-mumps-rubella
vaccine and autism controversy and its
relationship to MMR immunization rates in
the United States.
37.) A meta-analysis epidemiological
assessment of neurodevelopmental disorders
following vaccines administered from 1994
through 2000 in the United States.
38.) An evaluation of the effects of
thimerosal on neurodevelopmental disorders
reported following DTP and Hib vaccines in
comparison to DTPH vaccine in the United
States.
39.) Neurodevelopmental disorders following
thimerosal-containing childhood
immunizations: a follow-up analysis.
40.) Neurodevelopmental disorders after
thimerosal-containing vaccines: a brief
communication.
41.) A comparative evaluation of the effects
of MMR immunization and mercury doses from
thimerosal-containing childhood vaccines on
the population prevalence of autism.
42.) Aluminum adjuvant linked to Gulf War
illness induces motor neuron death in mice.
43.) Influenza vaccine with squalene
adjuvant: new preparation. No better than
available products.
44.) Antibodies to squalene in recipients of
anthrax vaccine.
45.)Aluminum hydroxide injections lead to
motor deficits and motor neuron degeneration.
46.) Aluminum-induced model of motor neuron
degeneration: subperineurial injection of
aluminum in rabbits.
47.) Vaccines as a trigger for myopathies.
48.) Induction of metallothionein in mouse
cerebellum and cerebrum with low-dose
thimerosal injection.
49.) Neonate exposure to thimerosal mercury
from hepatitis B vaccines.
50.) Secret CDC vaccine study Thimerosal an
autism risk
51.) Possible hidden hazards of mass
vaccination against new influenza A/H1N1:
have the cardiovascular risks been
adequately weighed?
52.) Adjuvants and autoimmunity.
53.)Oseltamivir-Resistant Influenza Virus A
(H1N1), Europe, 2007–08 Season
54.) Oseltamivir-Resistant Influenza Viruses
A (H1N1), Norway, 2007–08
================================================================
1.) MedImmune patentó el virus AH1N1 en 2008
================================================================
Source:Http://www.pijamasurf.com/2009/09/medimmune-patento-el-virus-a-h1n1-en-2008/
La controversia por esta extraña mutación
del virus de la influenza, conocida como
AH1N1, sigue y volverá a escalar,
particularmente cuando los gobiernos de la
mayor parte de los países del mundo efectuen
una campaña masiva de vacunación.
El problema es que según se reporta estas
vacunas tienen una serie de efectos
secundarios que harían palidecer al mismo
virus que buscan prevenir. Por una parte
Obama ha”inmunizado” legalmente a los
fabricantes. Por otra, al parecer el virus
H1N1 fue patentado por MedImmune desde 2008.
Baxter patentó una vacuna desde el 2008 y
Novartis en febrero de este año, y podría
haber participado en la fabricación del
virus desde 2005 o antes. El virus, una
gripe no demasiado peligrosa agravada por el
pánico, sería la excusa para la vacunación
global: un enorme negocio y posiblemente, en
la más oscura versión de la realidad, un
método de control poblacional y arma
biológica.
Medimmune tiene sus laboratorios en
Gaithersburg, Maryland, muy cerca de la base
militar Fort Detrick, antiguamente dedicada
a producir armas biológicos y donde se dice
se produjo el Antrax y otras armas
biológicas/virus.
MedImmune fue comprada por la farmacéutica
AstraZeneca en el 2007. La vacuna contra la
gripe A H1N1 que AstraZeneca está preparando
podría permitirle ingresar 2.300 millones de
dólares (1.600 millones) en los dos próximos
años. Esto permitiría a la farmacéutica
rentabilizar la prima del 21% que pagó al
comprar la biotecnológica MedImmune, unos
15.200 millones de dólares (10.674 millones
de euros) por encima de la capitalización
bursátil de la empresa en el momento de la
compra.
AstraZeneca está probando la tecnología de
spray nasal utilizada en su vacuna FluMist,
desarrollada MedImmune para el virus H1N1,
que infecta de la gripe A. En junio
MedImmune, con FluMist, ganó un contrato de
90 millones de dólares del Department of
Health and Human Services en Estados Unidos.
=======================================================
2.) Medimmune H1N1 Swine Flu Virus -
PATENT - 2008, Startling New Evidence That
The 'Swine Flu' Pandemic IsMan-Made
========================================================
Source:ttps://es.scribd.com/document/17718155/Startling-New-Evidence-That-The-Swine-Flu-Pandemic-Is-Man-Made
Startling New Evidence That The 'Swine
Flu' Pandemic IsMan-Made
Murder suspects are either convicted or
acquitted at trial based on the
prosecution's presentation of EVIDENCE
which usually hinges on MOTIVE,
OPPORTUNITY, and TIME-LINES combined
with physical documents. To gather such
hard evidence, detectives and/or federal
agents often spend monthsfollowing leads
and interviewing witnesses. In the trial
phase, re-creating the sequence of
events isessential. I submit this paper
will provide more than enough hard
evidence to at least result in a series
of criminal indictments of charges of
MASS MURDER, and CONSPIRACY TO COMMIT
WORLDGENOCIDE against Novartis
Pharmaceutical principals and agents and
others.
PRIMARY MOTIVE
The Primary Motive behind this alleged
criminal activity is also the primary
cause of most murders in theworld today,
and that motivation is simply: BIG
MONEY. Billions of Dollars of windfall
profits fromgovernment contracts
worldwide, as a matter of fact.I will
provide evidence that will show that
Novartis Pharmaceuticals of Basel,
Switzerland has conspiredwith corrupt "scientists"
at the U.S. Army Institute of Pathology
Ft. Detrick, Maryland, to create a "novel"strain
of weaponized "influenza" virus by means
of "reverse engineering" the deadly 1918
killer strainwhich strain was
maliciously and surreptitiously released
upon the world in March and April of
2009 for the primary purpose of creating
a panic-stricken world-wide demand for
Novartis vaccine material.The evidence
will also clearly show that the Novartis
vaccine material is in reality designed
to facilitatethe further mutation of the
pandemic into more lethal waves of
increasingly virulent and deadly
disease,rather than to curtail and limit
the existing outbreak. The evidence will
show that Novartis is willingly being
used, (and extremely well-paid) to
facilitate the edicts of the global
elite's Club of Rome; whichedicts
clearly call for a massive and sudden
depopulation of certain segments of the
earth's human population.
To realize such windfall profits on an
engineered, global flu pandemic,
detailed covert planning must take place
of course. Patents protecting the
proprietary flu vaccine must be applied
for and secured before the pandemic
virus is released in order to minimize
the competition and maximize the profit
potentials. In a biological attack of
this nature, timing is extremely
critical.Indeed, the evidence is clear
Novartis applied for just such a patent
on Nov. 4, 2005, and the U.S.
PatentOffice accepted this application
and granted US 20090047353A1 for a "Split
Influenza Vaccine withAdjuvants" on
February 19, 2009. (See bottom of page).With
this patent now secured, the
conspirators were now free to create the
demand for their "novel" splitinfluenza
vaccine by releasing a "novel" split-influenza
(combining multiple viruses) pandemic
virusfrom a weapons lab test-tube into
unsuspecting human hosts.http://www.washingtonpost.com/wp-dyn/content/article/2009/06/17/AR2009061703271.html
The so-called "Swine Flu" grabbing
headlines today is actually a
recombinant, or "split-influenza"
virusconsisting of A-strain Bird-Flu
(H5N1), Swine Flu (H1N1) and multiple
strains of human flu (H3N2).Likewise,
the 1918 Killer Flu that killed untold
millions of people was a recombinant or
"split-influenza"virus composed of Bird
flu, Swine Flu, and multiple strains of
human flu.
=======================================================================
3.) Roche Receives FDA Approval
Of TAMIFLU™, First Pill To Treat The
Most Common Strains Of Influenza
(A&B)
=======================================================================
Source:http://www.gilead.com/news/press-releases/1999/10/roche-receives-fda-approval-of-tamiflu-first-pill-to-treat-the-most-common-strains-of-influenza-ab
TAMIFLU™ (oseltamivir phosphate)
Decreases Duration of Flu Symptoms
NUTLEY, N.J. -- October 27, 1999
Hoffmann-La Roche Inc. and Gilead
Sciences, Inc. (NASDAQ:GILD),
announced today that Roche’s TAMIFLU™
(oseltamivir phosphate) has been
approved by the U.S. Food and Drug
Administration (FDA) for the
treatment of influenza A&B, which
includes all common strains of
influenza. TAMIFLU, the first
neuraminidase inhibitor in pill
form, will be available nationwide
in time for the arrival of this
year’s flu season.
TAMIFLU is indicated for the
treatment of uncomplicated acute
illness due to influenza infection
in adults who have been symptomatic
for no more than two days. The
recommended oral dose of TAMIFLU is
75 mg twice daily for five days.
Unlike over-the-counter medications
that only mask the symptoms of
influenza, TAMIFLU is an antiviral
agent that, based on in vitro data,
targets the actual influenza virus
and stops it from replicating from
cell to cell.
Co-developed with Gilead Sciences,
TAMIFLU is a systemic treatment for
influenza. The medication, part of a
new class of drugs called
neuraminidase inhibitors, targets
one of the two major surface
structures of the influenza virus,
the neuraminidase protein. The
neuraminidase site is virtually the
same in all common strains of
influenza. If neuraminidase is
inhibited, the virus is not able to
effectively replicate and spread to
other cells.
Two Phase III double-blinded,
placebo-controlled clinical trials
of TAMIFLU were conducted; one in
the U.S. and the other in
international sites. The two studies
enrolled a total of 849
influenza-infected patients, 18-65
years of age. Patients participating
in the trials were required to
self-assess the influenza-associated
symptoms as ‘none’, ‘mild’,
‘moderate’ or ‘severe’. Time to
improvement was calculated from the
time of treatment initiation to the
time when all symptoms (fever, nasal
congestion, sore throat, cough,
aches, fatigue, headaches, chills,
and sweats) were assessed as 'none’
or ‘mild’.
In both statistically significant
studies at the recommended dose,
there was a 1.3 day (30%) reduction
in the median time to improvement in
patients receiving TAMIFLU compared
to patients receiving placebo. The
most frequently reported adverse
events in these studies in patients
taking TAMIFLU were nausea and
vomiting and, to a lesser extent,
bronchitis, insomnia, and vertigo.
These events were generally mild to
moderate and transient. Less than 1%
of patients discontinued prematurely
from clinical trials due to nausea
and vomiting. TAMIFLU may be taken
with or without food. However, when
taken with food, tolerability may be
enhanced in some patients.
In an ongoing study of otherwise
healthy elderly patients, 65 years
of age and older, given the
recommended dose of TAMIFLU, there
was a reduction in the duration of
flu in patients receiving TAMIFLU
similar to that seen in younger
adults. Also, no overall difference
in safety was observed in clinical
trials between the elderly patients
and younger adults, and no dose
adjustments are required when
treating these populations.
“The timing of the FDA’s approval
for TAMIFLU is ideal,” said Dr.
Dominick Iacuzio, Medical Director,
Hoffmann–La Roche. “The early
arrival of the 1999-2000 flu season
means many Americans may be caught
short in taking preventive measures,
such as receiving their flu
vaccination. This early outbreak,
coupled with predictions of a severe
flu season, makes TAMIFLU a
welcome treatment alternative to
managing the misery of the flu.”
In clinical studies, TAMIFLU showed
no interference with the antibody
response to the influenza infection.
Use of TAMIFLU should not effect the
evaluation of patients for annual
influenza vaccination, in accordance
with the Centers for Disease Control
(CDC) guidelines.
“One of the advantages of TAMIFLU is
that it is administered orally,
which makes it not only convenient,
but allows the drug to be
distributed throughout the body,
reaching all key sites of infection,
including the upper and lower
respiratory tracts,” said Dr.
Frederick Hayden, a lead
investigator in the TAMIFLU studies
and the Stuart S. Richardson
Professor of Clinical Virology in
Internal Medicine and Professor of
Internal Medicine and Pathology at
the University of Virginia School of
Medicine.
Each year, up to 40 million
Americans develop the flu, an
average of about 300,000 are
hospitalized, and 20,000 to 40,000
people die from influenza and its
complications. The risks for
hospitalization and death from
influenza are higher among persons
aged 65 or older, and persons at any
age with underlying high risk
medical conditions. The economic
impact is high as well, costing the
United States an annual $14.6
billion in physician visits, lost
productivity, and lost wages.
About Hoffmann-La Roche and Gilead
Sciences
Hoffmann-La Roche Inc. is a leading
research-intensive pharmaceutical
company that discovers, develops,
manufactures and markets numerous
important prescription drugs that
improve, prolong and save the lives
of patients with serious illnesses.
Among the company’s areas of
therapeutic interest are: Virology,
including HIV/AIDS and hepatitis C;
Infectious Diseases, including
influenza; Cardiology; Neurology;
Oncology; Transplantation;
Dermatology; and Metabolic Diseases,
including obesity and diabetes.
The Company provides a wide range of
medications in the United States
through its marketing and sales
subsidiary, Roche Laboratories Inc.
Headquartered in Nutley, N.J., both
companies are members of the Basel,
Switzerland-based Roche Group, a
global leader in health care with
principal businesses in
pharmaceuticals, diagnostics,
vitamins, and fragrances and flavors.
For more information on Roche
Pharmaceuticals in the United States,
visit the company’s web site at:http://www.rocheusa.com
Gilead Sciences, headquartered in
Foster City, CA, is an independent
biopharmaceutical company that seeks
to provide accelerated treatment
solutions for patients and the
people who care for them. The
Company discovers, develops,
manufactures and commercializes
proprietary therapeutics for
challenging infectious diseases
(viral, fungal and bacterial
infections) and cancer. Gilead
maintains research, development or
manufacturing facilities in Foster
City, CA, Boulder, CO, San Dimas,
CA, and Cambridge, UK, and sales and
marketing organizations in the
United States, Europe and Australia.
Gilead common stock is traded on The
Nasdaq Stock Market under the symbol
GILD.
EDITOR’S NOTE: FOR MORE INFORMATION
ON INFLUENZA AND TAMIFLU, CONSUMERS
CAN LOG ONTOWWW.TAMIFLU.COM.
=======================================================================
4.) "Prepandemic" immunization for
novel influenza viruses, "swine flu"
vaccine, Guillain-Barré syndrome,
and the detection of rare severe
adverse events.
========================================================================
J Infect Dis. 2009 Aug
1;200(3):321-8. doi: 10.1086/603560.
Source:https://www.ncbi.nlm.nih.gov/pubmed/19563262
Author: Evans, David · Cauchemez,
Simon · Hayden, Frederick G
Author information
1
The Wellcome Trust, London,
United Kingdom. Journal The Journal
of infectious diseases
Abstract
The availability of immunogenic,
licensed H5N1 vaccines and the
anticipated development of vaccines
against "swine" influenza A(H1N1)
have stimulated debate about the
possible use of these vaccines for
protection of those exposed to
potential pandemic influenza viruses
and for immunization or "priming" of
populations in the so-called "prepandemic"
(interpandemic) era. However, the
safety of such vaccines is a
critical issue in policy development
for wide-scale application of
vaccines in the interpandemic
period. For example, wide-scale
interpandemic use of H5N1 vaccines
could lead to millions of persons
receiving vaccines of uncertain
efficacy potentially associated with
rare severe adverse events and
against a virus that may not cause a
pandemic. Here, we first review
aspects of the 1976 National
Influenza Immunization Programme
against "swine flu" and its
well-documented association with
Guillain-Barré syndrome as a case
study illustration of a suspected
vaccine-associated severe adverse
event in a mass interpandemic
immunization setting. This case
study is especially timely, given
the recent spread of a novel
influenza A(H1N1) virus in humans in
Mexico and beyond. Following this,
we examine available safety data
from clinical trials of H5N1
vaccines and briefly discuss how
vaccine safety could be monitored in
a postmarketing surveillance
setting.
========================================================================
5.) Vacuna contra gripe H1N1 está
bajo vigilancia por efectos
secundarios
========================================================================
04 Septiembre de 2009 por Sala de
Prensa - 3:35 pm
Source:http://www.vanguardia.com/historico/38744-vacuna-de-gripe-ah1n1-bajo-vigilancia-por-efectos-secundarios
Las vacunas contra la gripe H1N1 que
llegarán progresivamente al mercado
serán productos nuevos, con el
consiguiente riesgo de efectos
secundarios imprevistos, por lo que
las autoridades sanitarias
recomiendan que se estreche la
vigilancia una vez administradas.
No se pueden “conocer exactamente
sus efectos secundarios”, afirma la
red de expertos Infovac, creada para
los pediatras.
Infovac recuerda que las vacunas
similares producidas contra la gripe
aviaria “con los mismos coadyudantes
(sustancias que favorecen la
inducción de inmunidad)” provocan
“con más frecuencia relaciones
inflamatorias agudas que las vacunas
tradicionales contra la gripe
estacional”.
Esta red estima que “aún no se puede
excluir un riesgo raro (1 a 10 por
millón) de efectos indeseables
infrecuentes o graves”.
Si toda la población de Francia se
vacunara, como quiere el ministerio
de Sanidad francés, esto supondría
entre 60 a 600 casos de efectos
indeseables graves.
Para Margaret Chan, directora
general de la Organización Mundial
de la Salud (OMS), los ensayos
clínicos en curso deberían dar
indicios sobre los posibles efectos
secundarios de estas vacunas. Pero
debido “al número limitado de
personas sometidas a test, los
efectos secundarios extremadamente
raros no aparecen siempre en las
pruebas, explicó.
Recuerda que el síndrome de
Guillain-Barré, enfermedad
neurológica que puede ser grave,
“surge con una frecuencia de un caso
por un millón de personas vacunadas”.
“Corremos el riesgo por lo tanto de
tenerlos”, dice.
La OMS recomendó que se extreme la
vigilancia sanitaria tras la
inoculación de la vacuna.
Un sindicato de enfermeros teme “una
vacuna desarrollada demasiado
rápido”, con pruebas insuficientes,
y un coadyudante “susceptible de
activar enfermedades autoinmunes”.
“El remedio puede ser peor que el
mal”, afirma el Sindicato Nacional
de Profesionales Enfermeros ((SNPI)
francés. Reclama que los pacientes
firmen un documento de
consentimiento como se hace en el
caso de los medicamentos
experimentales.
Más de la mitad del personal
sanitario de Hong Kong, según un
estudio, se muestra reticente a
vacunarse. Lo mismo ocurre con las
enfermeras británicas, un 30% de las
cuales habría rechazado la vacuna,
según un sondeo publicado por una
revista profesional.
Algunos médicos recuerdan el
precedente estadounidense de 1976,
cuando por miedo a una epidemia de
gripe porcina se lanzó una campaña
de vacunación masiva que tuvo que
suspenderse ante la aparición de
síndromes de Guillain-Barré.
Pero Vincent Enouf, responsable
adjunto del Centro nacional de gripe
del Instituto Pasteur, sostiene que
nada ha permitido establecer que los
casos de Guillain-Barré surgidos en
1976 estuvieran “vinculados con la
vacunación”.
La bióloga Michèle Rivasi también
estima que parece “que se han
ignorado” los “riesgos” de la
vacunación a pesar de que la
“experimentación fue muy limitada”.
Señala con el dedo acusador a los
coadyudantes, gracias a los cuales
se estimula la inmunidad.
El profesor Daniel Floret,
presidente del Comité técnico de
vacunaciones, considera que el
riesgo de enfermedades autoinmunes
provocado por estos coadyudantes es
“teórico y en absoluto demostrado”,
aunque cree “legítimo” tomarlo en
consideración.
“El control de la calidad para la
producción de las vacunas
antigripales ha mejorado
sustancialmente desde los años
1970″, afirma la OMS, que recuerda
sin embargo en su página web que “la
vigilancia estrecha y la
investigación de todas las
manifestaciones indeseables graves
debidas a la administración de la
vacuna serán indispensables”.
==================================================================
6.) Vacuna influenza H1N1 genera
problema a fabricantes: FDA de
Estados Unidos
=================================================================
Source:http://lta.reuters.com/article/topNews/idLTASIE56M0UC20090723
11:00 AM Washington.- Los
fabricantes de la nueva vacuna
contra la gripe pandémica H1N1 sólo
están obteniendo un rendimiento del
30 por ciento en la inyección contra
esa cepa, comparado con el que
logran con la estacional, informaron
hoy funcionarios de la
Administración de Alimentos y
Medicamentos de Estados Unidos (FDA)
.
"El trabajo de desarrollo ha
indicado que las cepas de referencia
existentes tienen un rendimiento
esperando de alrededor del 30 por
ciento en las cepas de gripe H1N1",
dijo el doctor Jerry Weir, director
de la división de productos virales
de la FDA, en un encuentro de
asesores, reseñó Reuters.
Esto implica que los fabricantes
terminarán obteniendo menos dosis de
lo esperado de la vacuna contra la
cepa pandémica.
A comienzos de este mes, la
Organización Mundial de la Salud
(OMS) informó que los fabricantes de
vacunas no estaban obteniendo el
"rendimiento" esperado de las
muestras que se les enviaron del
virus de la popularmente conocida
como gripe porcina, que estaban
cultivando en huevos para luego
purificar y desarrollar vacunas.
La unidad MedImmune de AstraZeneca,
la australiana CSL Ltd, Baxter
International, GlaxoSmithKline Plc,
Novartis AG y Sanofi-Aventis SA
están fabricando vacunas contra la
cepa H1N1 y le informarán al comité
de la FDA lo que hayan aprendido
mientras trabajan con el virus.
Los Institutos Nacionales de Salud
de Estados Unidos informaron el
miércoles que habían programado para
agosto el comienzo de los ensayos
clínicos en humanos de las vacunas
de CSL y Sanofi, en varios centros y
clínicas del país. Pero la FDA debe
aprobar la iniciativa antes de su
inicio.
El Comité Asesor sobre Vacunas y
Productos Biológicos Relacionados de
la FDA se reunirá para evaluar esos
ensayos clínicos. Funcionarios de
salud indicaron que esperan poder
comenzar en octubre con la
vacunación en personas, siempre que
se aprueben las inmunizaciones.
========================================================================
7.) El Tamiflu, Donald
Rumsfeld y el negocio del miedo
=======================================================================
miércoles 29 de abril de 2009
source:Http://seniales.blogspot.com/2009/04/el-tamiflu-donald-rumsfeld-y-el-negocio.html
Por: José Antonio Campoy*
Bastó que Estados Unidos tocara
la campana de alarma para que el
mundo temblara de miedo ante la
perspectiva de una pandemia. A
pesar de que han transcurrido
nueve años desde que el famoso
virus de la gripe aviar fuera
detectado en Vietnam y no llegan
aún a cien las víctimas
mortales. Una media pues de once
fallecimientos al año… ¡en todo
el mundo! Un detalle
insignificante que no impidió a
George Bush emprender su segunda
“guerra preventiva” en poco
tiempo, esta vez para luchar
contra otra arma de destrucción
masiva tan vaporosa como las
“encontradas” en Irak: el virus
H5N1.
A fin de cuentas había hallado
también una poderosa “arma
preventiva”, un antiviral
llamado Tamiflu que
comercializaba la empresa suiza
Roche y que en apenas unos días
se convirtió en la gallina de
los huevos de oro. De hecho, los
ingresos por su venta pasaron de
254 millones en el 2004 a más de
1.000 millones en el 2005. Y su
techo es imprevisible dada la
grotesca reacción de los
gobiernos occidentales con
peticiones masivas del producto.
La realidad, sin embargo, es que
la eficacia del Tamiflu es
cuestionada por gran parte de la
comunidad científica. Muchos se
preguntan cómo se espera que
pueda servir ante un virus
mutante cuando apenas alivia
algunos síntomas -y no siempre-
de la gripe corriente.
Obviamente la respuesta al
protagonismo del Tamiflu en
nuestras vidas no es científica
sino puramente comercial. El
Tamiflu era hasta 1996 propiedad
de Gilead Sciences Inc. empresa
que ese año vendió la patente a
los laboratorios Roche. ¿Y saben
quién era entonces su
presidente? Pues el actual
Secretario de Defensa de Estados
Unidos, Donald Rumsfeld, que aún
hoy sigue siendo uno de sus
principales accionistas. ¿Y
recuerdan que pasó el año
pasado? Pues que en cuanto
empezó a hablarse de la gripe
aviar Gilead Sciences Inc quiso
recuperar el Tamiflu alegando
que Roche no hacía esfuerzos
suficientes por fabricarlo y
comercializarlo.
Y que tenía “fuerza” para
lograrlo lo demuestra que ambas
empresas se sentaron a
“negociar” y acordaron en un
tiempo récord constituir dos
comités conjuntos, uno que se
encargase de coordinar la
fabricación mundial del fármaco
y decidir sobre la autorización
a terceros para fabricarlo y
otro para coordinar la
comercialización de las ventas
estacionales en los mercados más
importantes, incluido Estados
Unidos. Además Roche pagó a
Gilead Sciences Inc unas
regalías retroactivas por valor
de 62,5 millones de dólares. Y
por si fuera poco la empresa
norteamericana se quedó con
otros 18,2 millones de dólares
extra por unas ventas superiores
a las contabilizadas entre 2001
y 2003. A lo que hay que añadir
un dato: Roche se ha quedado con
el 90% de la producción mundial
de anís estrellado, árbol que
crece fundamentalmente en China
-aunque también se encuentra en
Laos y Malasia- y que es la base
del Tamiflu. El escenario, qué
duda cabe, estaba completo.
Sólo había que empezar a
encontrar poco a poco aves
contagiadas con el virus en
distintos países -un ave aquí,
otro par más allá- para crear
alarma mundial con la ayuda de
científicos y políticos poco
escrupulosos o de escasa
capacidad intelectual y de los
grandes medios de comunicación
-que como todo el mundo sabe no
se caracterizan precisamente por
investigar lo que publican o
emiten-. ¿Y qué tiene que ver
Donald Rumsfeld en todo esto?
Pues absolutamente nada. Según
un comunicado emitido el pasado
mes de octubre por el Pentágono
el actual Secretario de Estado
norteamericano no intervino en
las decisiones que tomó el
Gobierno de sus amigos Bush -el
presidente- y Cheney -el
vicepresidente- sobre las
medidas preventivas que había
que adoptar ante la amenaza de
pandemia. El comunicado afirma
que se abstuvo, que no tuvo nada
que ver en la decisión de la
Administración estadounidense de
apoyar y aconsejar el uso del
Tamiflu a nivel mundial. Y
nosotros le creemos. Como cuando
aseguró solemnemente que en Irak
había armas de destrucción
masiva.
Además el hecho de que su nombre
aparezca unido a una vacunación
masiva contra una supuesta gripe
del cerdo durante la
Administración de Gerald Ford en
la década de los 70 -que dio
como resultado más de 50 muertos
a causa de los efectos
secundarios- no es más que una
coincidencia. Como lo es que la
FDA aprobara el aspartame a los
tres meses de que Rumsfeld se
incorporase al Gabinete de
Ronald Reagan a pesar de que
tras diez años de estudios no se
había tomado ninguna decisión.
Sólo alguien muy mal pensado
puede plantearse que tuviera
algo que ver el hecho de que
poco antes de incorporarse al
Gobierno norteamericano Rumsfeld
fuera el presidente del
laboratorio fabricante del
aspartamo. Y, por supuesto,
tampoco tuvo nada que ver con la
compra tras el 11-S del Vistide,
fármaco adquirido masivamente
por el Pentágono para evitar los
efectos secundarios que podía
producir la vacuna de la viruela
entre los soldados
norteamericanos a los que se les
aplicó masivamente antes de
enviarlos a Irak.
Que el Vistide fuera también un
producto de los laboratorios
Gilead Sciences Inc, creador del
Tamiflu, es otra coincidencia.
Así que siga usted de cerca
todas las informaciones que aún
van a darse sobre la gripe aviar
y llene su botiquín casero de
Tamiflu. Y si hay que comprar
algo más, se compra. Faltaba
más.
*Director de Discovery DSalud
La "pandemia”… ¿Será la gripe
aviar?
¿Sabes que el virus de la gripe
aviar fue descubierto hace 9
años en Vietnam?
¿Sabes que desde entonces han
muerto apenas 100 personas, en
todo el mundo todos estos años?
¿Sabes que los norteamericanos
fueron los que alertaron de la
eficacia del Tamiflu (antiviral
humano) como preventivo?
¿Sabes que el Tamiflu apenas
alivia algunos síntomas de la
gripe común?
¿Sabes que su eficacia ante la
gripe común está cuestionada por
gran parte de la comunidad
científica?
¿Sabes que ante un supuesto
virus mutante como el H5N1, el
Tamiflu apenas aliviara la
enfermedad?
¿Sabes que la gripe aviar hasta
la fecha sólo afecta a las aves?
¿Sabes quien comercializa el
Tamiflu? Laboratorios Roche.
¿Sabes a quién compró Roche la
patente del Tamiflu en 1996? a
Gilead Sciences Inc.
¿Sabes quien era el Presidente
de Gilead Sciences Inc y aun hoy
principal accionista?: Donald
Rumsfeld, ex-Secretario de
Defensa de USA.
¿Sabes que la base del Tamiflu
es el anís estrellado?
¿Sabes quien se ha quedado con
el 90% de la producción mundial
de este árbol?: Roche.
¿Sabes que las ventas del
Tamiflu pasaron de 254 millones
en el 2004 a más de 1000
millones en el 2005?
¿Sabes cuántos millones más
puede ganar Roche en los
próximos meses si sigue este
negocio del miedo?
O sea que el resumen del cuento
es el siguiente: los amigos de
Bush deciden que un fármaco como
el Tamiflu es la solución para
una pandemia que aún no se ha
producido y que ha causado en
todo el mundo 100 muertos en 9
años.
Este fármaco no cura ni la gripe
común. El virus no afecta al
hombre en condiciones normales.
Rumsfeld vende la patente del
Tamiflu a Roche y este le paga
una fortuna. Roche adquiere el
90% de
la producción del anís
estrellado, base del antivírico.
Los Gobiernos de todo el Mundo
amenazan con una pandemia y
compran a Roche cantidades
industriales del producto.
Nosotros acabamos pagando el
medicamento y Rumsfeld, Cheney y
Bush hacen el negocio….
Extractado de la Editorial del
número 81 (abril-2006) de la
revista DSalud Colaboración de
Irene Solera
=======================================================================
8.) The Tamiflu / Rumsfeld
Connection
=======================================================================
Forwarded email asserts a
conspiratorial connection
between the worldwide alarm over
a possible flu pandemic and
Donald Rumsfeld's financial
interest in the company that
patented the antiviral drug
Tamiflu.
Source:Http://http://urbanlegends.about.com/library/bl_bird_flu.htm
broken link
Description: Email rumor
Circulating since: April 2006
Status: Partly true
Email example contributed by
Jennie R., April 28, 2006:
Subject: BIRD FLU - US
PROPAGANDA!
"Bird Flu"
Do you know that 'bird flu' was
discovered in Vietnam 9 years
ago?
Do you know that barely 100
people have died in the whole
world in all that time?
Do you know that it was the
Americans who alerted us to the
efficacy of the human antiviral
TAMIFLU as a preventative.
Do you know that TAMIFLU barely
alleviates some symptoms of the
common flu?
Do you know that its efficacy
against the common flu is
questioned by a great part of
the scientific community?
Do you know that against a
SUPPOSED mutant virus such as
H5N1, TAMIFLU barely alleviates
the illness?
Do you know that to date Avian
Flu affects birds only?
Do you know who markets TAMIFLU?
ROCHE LABORATORIES.
Do you know who bought the
patent for TAMIFLU from ROCHE
LABORATORIES in 1996?
GILEAD SCIENCES INC.
Do you know who was the then
president of GILEAD SCIENCES
INC. and remains a major
shareholder? DONALD RUMSFELD,
the present Secretary of Defence
of the USA.
Do you know that the base of
TAMIFLU is crushed aniseed?
Do you know who controls 90% of
the world's production of this
tree?
ROCHE.
Do you know that sales of
TAMIFLU were over $254 million
in 2004 and more than $1000
million in 2005?
Do you know how many more
millions ROCHE can earn in the
coming months if the business of
fear continues?
So the summary of the story is
as follows:
Bush's friends decide that the
medicine TAMIFLU is the solution
for a pandemic that has not yet
occurred and that has caused a
hundred deaths worldwide in 9
years.
This medicine doesn't so much as
cure the common flu.
In normal conditions the virus
does not affect humans.
Rumsfeld sells the patent for
TAMIFLU to ROCHE for which they
pay him a fortune. Roche
acquires 90% of the global
production of crushed aniseed,
the base for the antivirus.
The f the entie world threaten a
pandemic and then buy industrial
quantities of the product from
Roche.
So we end up paying for medicine
while Rumsfeld, Cheney and Bush
get richer, thank the RED
STATES!
Comments: Is U.S. Secretary of
Defense Donald Rumsfeld
personally profiting from fears
that a worldwide bird flu
pandemic may occur? Yes.
Rumsfeld once served as chairman
of Gilead Sciences, Inc., the
company that holds the patent on
the antiviral drug Tamiflu,
currently regarded as the
world's best hope for the
prevention and treatment of
avian influenza. He still owns
Gilead stock valued at between
$5 million and $25 million.
Is it true that no one really
knows whether avian influenza
will mutate and take hold in the
human population, let alone
reach pandemic proportions? Yes.
For now, the disease remains
mostly confined to the bird
population, and the number of
cases of bird-to-human
transmission remains relatively
small.
Do you believe there's a
conspiracy afoot to spread fear
of a bird flu pandemic so
members of the Bush
administration can profit?
Yes.
No.
Not sure.
Current Results
Must we therefore conclude that
the alarm raised over a possible
pandemic and the rush to
stockpile Tamiflu amount to a
conspiracy to line the pockets
of G.W. Bush's cronies? Not
necessarily. One strain of the
bird flu virus, H5N1, has
demonstrated a high mortality
rate in both birds and people,
and the concern is that it could
mutate into much more contagious
form in humans. The World Health
Organization considers the risk
of a pandemic "serious."
Bird flu threat overestimated?
Granted, there are well-informed
skeptics in the scientific
community who argue that public
health officials have
overestimated the threat of a
pandemic - and the skeptics
could be right - but the "better
safe than sorry" approach is too
widespread to be discounted as
an aberration of the Bush
administration. The World Health
Organization, the health
ministries of China, Japan and
other Asian countries, and the
health commissioner of the
European Union have all called
for bird flu preparedness plans
that include the stockpiling of
Tamiflu.
Sorting fact from error
The forwarded text advancing
these claims was paraphrased
from an editorial that appeared
in the April 2006 issue of the
Spanish health magazine
Discovery DSalud. Albeit in much
briefer form, the email captures
the spirit and message of the
orginal column. There are
factual errors, however, some of
which can be found in the
original, some of which may be
due to mistranslation, and some
of which probably crept into the
text during transmission:
* CLAIM: Bird flu was discovered
in Vietnam nine years ago.
NOT EXACTLY. Avian flu strain
H5N1 was first isolated in human
beings nine years ago - in Hong
Kong, not Vietnam. The first
reported cases in Vietnam
occurred in 2003.
* CLAIM: Barely 100 people have
died in the whole world in all
that time.
TRUE. As of this writing, the
official human death toll from
bird flu since 2003 is 115.
Counting the six who died in
Hong Kong in 1997, the nine-year
total is 121.
* CLAIM: "...it was the
Americans who alerted us to the
efficacy of the human antiviral
Tamiflu as a preventative."
PROBABLY TRUE. The Georgia-based
Centers for Disease Control and
Prevention announced as early as
2004 that the antiviral drug
oseltamivir phosphate (Tamiflu),
already proven successful in the
prevention and treatment of the
common flu, was likely to prove
similarly effective against the
avian influenza virus.
* CLAIM: Tamiflu barely
alleviates some symptoms of the
common flu.
MISLEADING. Antiviral
medications like Tamiflu attack
the flu virus itself, not
specific symptoms. Even so,
Tamiflu has been shown in
clinical trials to reduce the
severity of common flu symptoms,
shorten the duration of the
illness by an average of 37
percent, and reduce the number
of complications in otherwise
healthy individuals.
* CLAIM: Tamiflu's efficacy
against the common flu is
questioned by a great part of
the scientific community.
FALSE. A search of the available
medical literature on Tamiflu
yielded no evidence of
significant controversy
regarding its efficacy against
the common flu.
* CLAIM: "...against a SUPPOSED
mutant virus such as H5N1,
Tamiflu barely alleviates the
illness."
UNSUBSTANTIATED. While the
efficacy of Tamiflu against
H5N1, the most pathogenic strain
of bird flu, has yet to be
assessed in clinical trials, its
effectiveness has been
sufficiently verified in animal
and in vitro studies to earn the
recommendation of the World
Health Organization for the
treatment and prevention of
H5N1.
* CLAIM: To date, avian flu
affects birds only.
FALSE. Not to mention
self-contradictory and
nonsensical. As confirmed above,
over 100 human beings worldwide
have died of avian flu in the
past three years. Clearly it
doesn't affect birds only.
* CLAIM: "Do you know who
markets Tamiflu? ROCHE
LABORATORIES."
TRUE. Roche is a pharmaceutical
manufacturer based in
Switzerland.
* CLAIM: "Do you know who bought
the patent for Tamiflu from
ROCHE LABORATORIES in 1996?
GILEAD SCIENCES INC."
GARBLED. Gilead Sciences, Inc.
discovered Tamiflu in the early
1990s and still holds the
patent. Gilead licensed
development and marketing rights
to Roche in 1996.
* CLAIM: "Do you know who was
the then president of GILEAD
SCIENCES INC. and remains a
major shareholder? DONALD
RUMSFELD, the present Secretary
of Defence of the USA."
TRUE. According to Fortune
magazine, Rumsfeld was Gilead's
chairman from 1997 to 2001. It's
unknown exactly how many shares
he still owns in the company,
but the value of his holdings is
estimated at between $5 million
and $25 million.
* CLAIM: the "base" of Tamiflu
is crushed aniseed.
TRUE. One of the basic
ingredients of Tamiflu is
shikimic acid, the main source
of which is currently star
anise, a spice grown in China.
However, there are r methods of
making shikimic acid,nd Roche is
already looking at ways to
reduce its dependence on the
star anise supply.
* CLAIM: "Do you know who
controls 90% of the world's
production of this tree? ROCHE."
FALSE. According to a November
2005 report in the Washington
Post, only about half of China's
entire stock of star anise goes
to pharmaceutical manufacturers,
including Roche.
* CLAIM: Sales of Tamiflu were
over $254 million in 2004 and
more than $1 billion in 2005?
ROUGHLY ACCURATE. According to
Forbes magazine, Tamiflu sales
totalled $258 million in 2004
and were projected to exceed $1
billion in 2005.
=======================================================================
9.) Donald Rumsfeld's
controversial links to drug
company behind Tamiflu
======================================================================
By Mail on Sunday Reporter
UPDATED: 22:04 BST, 2 May 2009
Source:http://www.dailymail.co.uk/news/article-1176743/Donald-Rumsfelds-controversial-links-drug-company-Tamiflu.html#ixzz4sFKpQKxu
The drug company behind the
swine flu medicine Tamiflu is at
the centre of controversy over
its links to former US Defence
Secretary Donald Rumsfeld.
Mr Rumsfeld, a former chairman
of the company, has refused to
comment on whether he still
holds shares in Californian firm
Gilead Sciences, which developed
the drug now being desperately
stockpiled by governments around
the world to combat the
threatened pandemic.
Last night an associate of Mr
Rumsfeld said: ‘He does not
publicly discuss his private
finances.’
However, should Mr Rumsfeld have
held on to shares in the
company, he would be a major
beneficiary of the surge in the
global demand for the drug. The
NHS alone has already purchased
enough Tamiflu to treat
three-quarters of the population
in the UK.
Mr Rumsfeld has previously been
accused of a potential conflict
of interest over his links to
Gilead Sciences, which sold the
licensing rights for the
medicine to Swiss giant
Hoffman-La Roche in 1996.
Under the terms of the deal
Gilead, headed by Mr Rumsfeld
between 1997 and 2001, still
receives between 14 and 22 per
cent of the income from the
wholesale trade in the drug,
depending on the volume of
sales.
Four years ago the value of Mr
Rumsfeld’s shares in Gilead
Sciences saw a huge hike from an
estimated £3million to an
estimated £17million over the
avian flu scare.
It was partially sparked by a
warning from President Bush’s
top health adviser Mike Leavitt
that a pandemic could cause
nearly two million deaths in the
US alone.
Thousands take 'swine flu
sickies' as number of British
cases hits 15
Is this the first celebrity
swine flu victim? Chart-topping
N-Dubz singer Tulisa in
isolation ward with...
'I've never experienced anything
like it': England's first victim
to contract swine flu from
another human...
'The smell is so awful that I
start to vomit': Is this farm
the Ground Zero of swine flu?
When details of Mr Rumsfeld’s
shareholding became public he
consulted a lawyer who advised
him to keep the stock but excuse
himself from any government
decisions involving the flu
drug.
He issued a document explaining
the situation. Some months later
the Pentagon ordered £39million
worth of the Tamiflu drug for US
troops.
tamiflu
When details of Mr Rumsfeld's
shareholding became public he
was advised to keep the stock
but excuse himself from
government decisions
Dr Joseph Mercola, author of The
Great Bird Flu Hoax, said
yesterday: ‘The only thing all
this talk of swine flu does is
spread fear. President Bush
sought to instil panic by
telling us a minimum of 200,000
people will die from avian flu
but it could be as bad as two
million deaths in the US alone.
This hoax was justified by the
immediate purchase of 80million
doses of Tamiflu.’
As well as Mr Rumsfeld, Gilead
has links with a number of other
Republican figures. The largest
shareholder is FMR Corporation,
owned by Grover Glenn Norquist,
a Republican activist.
And George Schultz, President
Ronald Reagan’s former Secretary
of State, was a major
shareholder until he sold his
stake in 2005, netting around
£5million.
Gilead has announced record
first-quarter results, with
revenues of £1billion, although
a lot of revenue came from their
AIDS drugs.
Michael Riordan, 51, the founder
of Gilead who retired in 1997,
said yesterday: ‘If the company
has been successful, it’s not
because of any political
affiliations.’
=======================================================================
10.) China anuncia primera
vacuna contra Gripe Porcina H1N1
=======================================================================
jueves, 03 de septiembre de 2009
Source:http://hunnapuh.blogcindario.com/2009/09/03271-china-anuncia-primera-vacuna-contra-gripe-porcina-h1n1.html
La agencia oficial de
comunicaciones Chinas XINHUA,
anunció que china logró hoy la
licencia de producción de la
primera vacuna específica contra
la gripe Porcina o H1N1, la
empresa farmacéutica China
Sinovac Biotech, fue la
responsable de este avance, el
nombre que han dado a dicha
vacuna es "Panflu.1".
"La vacuna H1N1 de Sinovac está
aprobada oficialmente", declaró
en conferencia de prensa el jefe
de la SFDA (Autoridad Estatal de
Alimentos y Medicamentos), Zhang
Wei, luego añadió, "El conjunto
de pruebas de la vacuna de
Sinovac muestra que la vacuna es
muy segura".
"China ha avanzado muy
rápidamente en este tema y
podemos felicitarlos por haber
compartido con nosotros los
resultados de las pruebas",
declaró la directora del
servicio de vacunas de la OMS,
Marie-Paule Kieny
Existe otra vacuna China que
está en espera de los resultados
de las pruebas y que aspira a
convertirse en la segunda vacuna
contra la gripe porcina, se
trata de la empresa farmacéutica
Hualan Biological Engineering
Inc. tambióen de China.
En todo el mundo hay como 8
vacunas mas que están en la
etapa de pruebas para poder
recibir la autorización, pero
esta vez los gigantes
farmaceuticos se quedaron atras
y los Chinos toman la delantera
científica y tecnológica.
El laboratorio Sinovac espera
alcanzar una meta de producción
de 2 millones de dosis mensuales.
En europa se han recibido ya las
primeras dosis pero aún no se
tiene la autorización para
comercializarlas.
========================================================================
11.) Baxter, los virus de la
gripe extraviados y el plasma
sanguíneo contaminado.
========================================================================
Source:http://www.migueljara.com/2009/10/13/baxter-los-virus-de-la-gripe-extraviados-y-el-plasma-sanguineo-contaminado/
Publicado por Miguel Jara el 13
de Octubre de 2009.
Quisiera en esta información
tratar sobre una de las cosas
que más llama la atención del
video ya famoso de la monja
benedictina y médica Teresa
Forcades:
Cuenta que a finales de enero de
2009, la filial austríaca de la
farmacéutica norteamericana
Baxter, especializada en la
fabricación de vacunas, entre
otros preparados, distribuyó a
16 laboratorios de Austria,
Alemania, la República Checa y
Eslovenia, 72 kilogramos de
material para preparar miles de
vacunas contra el virus de la
gripe estacional. Las vacunas
tenían que ser administradas a
la población de estos países
durante los meses de febrero y
marzo. Antes de que ninguna de
estas vacunas fuese
administrada, un técnico de
laboratorio de la empresa
BioTest de la República Checa
decidió por su cuenta probar las
vacunas en hurones, que son los
animales que desde 1918 se
utilizan para estudiar las
vacunas de la gripe. Todos los
hurones vacunados murieron. Se
investigó entonces en qué
consistía exactamente el
material enviado por la casa
Baxter y se descubrió que
contenía virus vivos de la gripe
aviar (virus A/H5N1) combinados
con virus vivos de la gripe de
cada año (virus A/H3N2). Si esta
contaminación no se hubiese
descubierto a tiempo -prosigue
Forcades-, la pandemia que “sin
base real están anunciando las
autoridades sanitarias globales
y nacionales”, ahora sería una
“espantosa realidad”. Esta
combinación de virus vivos puede
ser especialmente letal porque
combina un virus que tiene un 60
de mortalidad pero es poco
contagioso (el virus de la gripe
aviar) con otro que tiene una
mortalidad muy baja pero con una
gran capacidad de contagio (un
virus de los de la gripe de cada
año).
A menudo nos llegan
informaciones de este tipo que
podemos pensar que pertenecen
más bien al campo de la ciencia
ficción. Pero ¿y si el
laboratorio del que tratamos,
Baxter, ya se hubiera visto
implicado en el pasado en hechos
cuando menos similares? Muchos
de ustedes han leído mi primer
libro, Traficantes de salud:
Cómo nos venden medicamentos
peligrosos y juegan con la
enfermedad.
Recordarán que en el primer
capítulo de todos trato el caso
de las personas muertas en
España tras el contagio de su
sangre con los virus de la
hepatitis C y de sida (al menos
unas 1.600). Estos sucesos se
desarrollaron en los años
ochenta y se prolongaron durante
los noventa e incluso ya
entrados en la década de 2000
había personas que fallecían por
los problemas que les habían
causado lustros antes. Había
varios laboratorios implicados y
uno de ellos era Baxter que
había comercializado su
hemoderivado Hemofil
contaminado. Como me contaría
Josefa Lorenzo, uno de los pocos
padres que se atrevieron a
denunciar a los laboratorios y a
la administración tras la muerte
de sus hijos:
“Los laboratorios no tomaron las
medidas oportunas para evitar la
exclusión como donantes de
personas que podían transmitir
la nueva enfermedad y no se
avisó a los hemofílicos del
riesgo que suponía la
administración de dichos
preparados. Todo esto a pesar de
que en los años ochenta los
científicos conocieron el riesgo
que suponía administrar
derivados sanguíneos a los
hemofílicos”.
Pero hubo más. Nuestro país no
fue el único donde ocurrieron
estos hechos. En Francia el
escándalo fue mayúsculo. Se
contagiaron unas 4.400 personas
y varios ministros del gobierno
galo fueron juzgados y el de
Sanidad hallado culpable. En
Canadá, entre los años 1986 y
1990, alrededor de 6.500
personas resultaron infectadas
con Hepatitis C a través de
transfusiones de sangre y
derivados sanguíneos. Al menos
1.000 hemofílicos que padecieron
sida y Hepatitis C y B en este
país recibieron tratamiento con
productos tóxicos procedentes de
prisiones de EE.UU. Hasta 1983
las compañías farmacéuticas
acudieron a estos centros
penitenciarios para “recaudar”
la sangre “donada” por los
condenados de aquel país. Canadá
dejó de utilizar este método en
1971 porque la mayoría de los
presidiarios estaban infectados
con Hepatitis. Pese a haber
tardado doce años en adoptar la
misma medida que su vecino del
norte a los reclusos
estadounidenses continuaron
extrayéndoles sangre para
satisfacer a la clientela
farmacéutica. Michael Galster,
que trabajó en el grupo de
médicos del sistema
penitenciario de Arkansas
durante la época en la que
ocurrieron los hechos, escribió
un libro denunciando estos
hechos vividos en su práctica
cotidiana.
La sangre recogida de personas
enfermas en las prisiones fue
importada, entre otros países,
por España. No cabe duda que en
nuestro país entró plasma
sanguíneo con muchas
posibilidades, por mostrarme
prudente, de estar contaminado
con la Hepatitis B. Así lo
advirtieron las autoridades
canadienses a las españolas. Con
todo lujo de detalles añadían
los lotes concretos que habían
llegado a la Península, como
documento en el libro. El
laboratorio implicado en este
caso, el que importó el plasma
de otra empresa fue Landerlan,
ya desaparecido como tal
======================================================================
12.) OMS a juicio por
Bioterrorismo por la Gripe
Porcina
=======================================================================
Source:Http://www.cherada.com/articulos/oms-a-juicio-por-bioterrorismo-por-la-gripe-porcina
Publicado por: Sauron el 25 / 07
/ 2009 a las 12:59 am.
Según la denuncia, los gobiernos
y multitud de organismos
internacionales implicados en
una trama de reducir la
población mundial. Una
periodista de investigación de
Austria alerta al mundo de que
el mayor crimen en la historia
de la humanidad está en marcha.
Bárbara Minton, editora del
popular sitio de información
sobre la salud, Natural News,
presenta una investigación
efectuada por una periodista
austríaca, Jane Bürgermeister,
que denuncia a grandes
laboratorios, la OMS y hasta al
presidente de USA, Barack Obama,
de ser parte de un plan de
vacunación masiva contra la
gripe porcina que tendría como
fin real reducir la población
mundial significativamente
Jane Bürgermeister ha presentado
al FBI cargos criminales contra
de la Organización Mundial de la
Salud (OMS), las Naciones Unidas
(ONU), y funcionarios de
Gobiernos y empresas en relación
con el bioterrorismo e intentos
de cometer asesinatos en masa.
En julio del 2009 se espera que
esté lista la vacuna de Baxter
contra la gripe A/H1N1 que
piensa ser empleada como "arma
de destrucción masiva".
La denunciante también ha
preparado un mandamiento
judicial contra la vacunación
que se está presentado en
América. Se presentan cargos
contra Baxter AG y Avir Green
Hills Biotechnology de Austria
por producir vacunas contra la
gripe empleando para ello aves
contaminadas, alegando que se
trataba de un acto deliberado de
provocar y sacar provecho de una
pandemia.
Resumen de las reclamaciones y
denuncias presentadas ante el
FBI en Austria el 10 de junio,
2009
En su acusación, Bürgermeister
presenta pruebas de los actos de
bioterrorismo en violación de la
ley de EE.UU, por un grupo que
opera en los EE.UU bajo la
dirección de los banqueros
internacionales que controlan la
Reserva Federal, así como la
OMS, la ONU y la OTAN con el fin
de llevar a cabo un genocidio en
masa contra la población de los
EE.UU. mediante el uso de la
ingeniería genética una pandemia
de gripe de virus con la
intención de causar la muerte.
Este grupo ha elevado anexo de
las oficinas gubernamentales en
los EE.UU.
Cargos penales relativos a actos
Bioterrorismo y el asesinato en
masa.
EMBAJADA DE LOS ESTADOS UNIDOS
Boltzmanngasse 16 A-1090 Viena
Austria
Fecha: 10 de junio de 2009
I. Introducción: Resumen de las
reivindicaciones
II. Antecedentes de hecho
III. Prueba de la gripe porcina,
las vacunas son armas biológicas
IV. Pruebas científicas el virus
de la gripe porcina es
artificial (ingeniería genética)
del virus.
V. Las pruebas científicas de
que la gripe porcina se asemeja
genéticamente al de la gripe
española de 1918, el virus
asesino.
VI. Secuencia del genoma de la
gripe porcina
VII. Pruebas de liberación del
virus de la gripe porcina en
México
VIII. Pruebas de la
participación del Presidente
Obama
IX. Pruebas de la función de
Baxter y la OMS en la producción
y liberación de la pandemia del
virus de material en Austria.
X. Prueba de que Baxter es un
elemento encubierto de armas
biológicas que opera en una red.
XI. Prueba de que Baxter ha
contaminado deliberadamente las
drogas.
XII. Prueba de que las vacunas
de Novartis están siendo
utilizadas como armas
biológicas.
XIII. Pruebas de la función de
la OMS en el programa de armas
biológicas: proveedor de los
virus de la gripe aviar a Baxter
XIV. Pruebas de que la OMS está
manipulando los datos de la
enfermedad con el fin de
justificar la declaración de una
pandemia Nivel 6 con el fin de
tomar el control de los EE.UU..
XV. Pruebas de la función de la
FDA en la cobertura de programa
de armas biológicas
XVI. Pruebas de la Nacional de
Microbiología de Canadá de los
laboratorios en el programa de
armas biológicas
XVI. Pruebas de la participación
de los científicos que trabajan
para el Reino Unido de NIBSC, y
el CDC en la ingeniería de la
gripe porcina.
XVII. Prueba de que las vacunas
asesinas causaron la gripe
española de 1918.
XVIII. Precedentes: la gripe
porcina y el programa de
vacunación masiva de 1976
XIX. Resultados insuficientes
del gobierno para detener la
propagación de la gripe porcina
como cobertura para la difusión
de una pandemia
XX. Pruebas de la manipulación
del marco jurídico para permitir
el asesinato en masa con total
impunidad
XXII. Cuestiones
constitucionales: la necesidad
de actuar desde la legalidad
para poner punto y final a la
ilegalidad de poner en peligro
la vida, la salud y el bien
público en un sistema de
vacunaciones en masa
XXI. El tema de la inmunidad y
la indemnización como prueba de
la intención de cometer un
delito
XXII. Pruebas de la utilización
de la reducción de la población
por medio de Chemtrails
XXIII. Pruebas de la existencia
de un sindicato internacional de
delincuencia empresarial a nivel
global.
XXIV. Pruebas de la existencia
de la organización llamada
Illuminati
XXV. Pruebas de la participación
de los Illuminati en el actual
colapso del sistema financiero
mundial
XXVI. Pruebas del objetivo en la
agenda Illuminati de depoblación
a nivel mundial; El Club
Bilderberg y su participación en
la ingeniería y la liberación de
virus artificial de la gripe
porcina.
XXVII. Pruebas de la Agenda de
genocidio por medio de la gripe
en armas que se debate en la
reunión anual de Bilderberg en
Atenas a partir de mayo (en los
días del 14 al 17) de 2009
XXX Acusados. Adjuntos ? Cargos
penales presentadas contra
Baxter y la OMS, entre otras
cosas, en Austria ? Cargos
penales presentados contra
Baxter y la OMS, entre otras
cosas, en Suiza ? respuestas de
Baxter al incidente- Extracto:
sobre las armas biológicas, la
Ley contra terrorismo de 1989
I. Introducción:
Presento las pruebas de las
alegaciones de los actos de
bioterrorismo en violación de la
legislación penal de los Estados
Unidos, llevados a cabo por un
grupo que opera en los Estados
Unidos, bajo la dirección de un
grupo de banqueros
internacionales que controlan,
entre otras cosas, las
instituciones financieras, la
Reserva Federal, así como las
organizaciones gubernamentales
internacionales, en particular
la Organización Mundial de la
Salud, las Naciones Unidas y la
OTAN.
Aquí se presentan las pruebas
con objeto de demostrar que un
sindicato internacional dedicado
al crimen, que opera por medio
de estas empresas, tiene la
intención de llevar a cabo un
genocidio en masa contra la
población de los Estados Unidos
mediante el uso de un producto
biológico creado por medio de
ingeniería genética.
Específicamente, se presentan
pruebas contra los siguientes
Demandados :
Presidente Barack Obama,
Presidente de los Estados
Unidos,
David Nabarro, Coordinador del
Sistema de las Naciones Unidas
para la Gripe,
Margaret Chan, Directora General
de la Organización Mundial de la
Salud,
Kathleen Sibelius, Secretario
del Departamento de Salud y
Servicios Humanos (HHS ),
Secretario,
Janet Napolitano, el
Departamento de Seguridad
Interior,
David de Rothschild, banquero,
David Rockefeller, banquero,
George Soros, el banquero,
Werner Faymann, Canciller de
Austria,
Alois Stöger, Ministro de Salud
de Austria
Todas estas personas son parte
de una organización criminal de
empresas que ha desarrollado,
producido, almacenado y empleado
armas biológicas para eliminar
la población de los Estados
Unidos y de otros países con
objeto de obtener beneficios
políticos y financieros.
Se presentan pruebas de que los
acusados conspiran entre sí , y
con otros para diseñar,
financiar y participar en la
fase final de la ejecución de un
programa encubierto de armas
biológicas a nivel internacional
que implica, entre otras
entidades, a las empresas
farmacéuticas Baxter y Novartis,
quienes, por medio de
bioingeniería y posterior
liberación de agentes biológicos
letales, en primer lugar, el
llamado virus de la gripe aviar
y, en segundo lugar, el llamado
virus de la gripe porcina,
pretenden poner en marcha un
programa de vacunación masiva
forzada, que será el medio para
la administración de un agente
biológico tóxico.
Dicho agente causará muerte y
lesiones a la población de los
Estados Unidos al entrar en el
organismo por medio de
inyecciones; todo ello en un
acto de violación de las Armas
Biológicas Ley Antiterrorista de
1989 (BWATA), aprobada en 1990,
que amplió el ámbito de los bio-
materiales de guerra a fin de
incluir en dicha regulación a
particulares y organizaciones no
estatales, incluidas las
empresas del sector farmacéutico.
El expediente aportado presenta
pruebas de que Baxter AG, filial
austriaca de Baxter
Internacional, con sede en
Deerfield, Ill, deliberadamente,
a sabiendas y voluntariamente,
envió 72 kilos de virus de la
gripe de aves vivas,
suministrados por la
Organización Mundial de la Salud,
Ginebra, Suiza en el invierno de
2009 a 16 laboratorios en cuatro
países. Estas pruebas ofrecen
una prueba clara de que las
empresas farmacéuticas
internacionales y los organismos
gubernamentales están
participando activamente en la
elaboración, desarrollo,
fabricación y distribución de
agentes biológicos como el más
mortal arma biológica en el
planeta con el fin de
desencadenar una pandemia y
causar muertes en masa.
El Anexo (A) es una copia de los
cargos penales presentados
contra Baxter y otros acusados
en la ciudad de Viena Fiscalía
8t de abril de 2009. La policía
austríaca están investigando el
incidente de la liberación de 72
kilos de aves vivas del virus de
la gripe de Baxter laboratorio
Orth an der Donau este invierno.
La pandemia de la gripe porcina
se basa en una gran mentira que
asegura que el virus es de
origen natural y que representa
una amenaza para la población.
Se ofrece clara prueba y
evidencia científica de que el
virus de la gripe aviar y el
virus de la gripe porcina, de
hecho, han sido diseñados por
bioingeniería en laboratorios,
utilizando fondos suministrados
por la OMS y otros organismos
gubernamentales, entre otros.
Este virus de la gripe porcina
es un híbrido, de gripe porcina,
y de de gripe aviar, algo que
sólo puede provenir de un
laboratorio, según los propios
expertos.
La OMS afirma que la gripe
porcina se está extendiendo y
declara una pandemia haciendo
caso omiso de las causas que la
producen. Los virus que fueron
puestos en libertad fueron
creados y puestos en libertad
con la ayuda de la OMS y la OMS
es responsable de la abrumadora
pandemia, en primer lugar, por
no introducir medidas para
limitar la propagación del virus
con rapidez. Por otro lado, los
síntomas de la gripe porcina son
indistinguibles de los
periódicos de la gripe o
resfriado común.
El virus, que se supone causante
de la gripe, no causa muerte con
mayor intensidad que la gripe
ordinaria. Las cifras de muertes
registradas por la gripe porcina
son incompatibles con la alarma
levantada y no hay claridad en
cuanto a la forma en que el
número de muertes se está
documentando.
Sin embargo, hay motivos
razonables para creer que en las
vacunas obligatorias se
introducen sustancias
contaminadas que están
específicamente diseñadas para
causar la muerte. Una licencia
de vacuna de la empresa
farmacéutica Novartis contra la
gripe aviar mató, al menos, a 21
personas sin techo en Polonia
durante el verano de 2008 y tuvo
como principal resultado una
alta tasa de efectos adversos,
cumpliendo así con la propia
definición de arma biológica
(una agente biológico destinado
a causar una alta tasa de
eventos adversos, es decir, la
muerte o lesiones), mediante un
sistema de prestación de
servicios (inyecciones de
vacunas).
La misma red de compañías
farmacéuticas internacionales y
los organismos gubernamentales
que han desarrollado y liberado
los materiales relacionados con
esta pandemia se han posicionado
en el mercado para beneficiarse
económicamente tras desencadenar
la pandemia, sellando
previamente contratos de
suministro de dicha vacuna y su
financiación. La pandemia traerá
enormes beneficios económicos
para la industria farmacéutica,
relacionados con la posible
venta de vacunas contra la gripe
porcina, por medio de
subvenciones y financiación.
Los diferentes grupos de medios
de comunicación están
controlados por el mismo grupo
que se encarga de esta gripe
porcina alimentando por medio de
desinformación a los ciudadanos
con objeto de que sean
destinatarios de la peligrosa
vacuna.
En resumen, el expediente
presenta pruebas de que el
pueblo de los Estados Unidos va
a sufrir un perjuicio
considerable e irreparable si
los ciudadanos se ven obligados
a recibir esta vacuna sin su
consentimiento informado de
acuerdo con el modelo de Estado
de Emergencia de Salud Ley de
poderes, la Ley de Emergencia
Nacional, la seguridad nacional
la Directiva Presidencial / NSPD
51 y SEGURIDAD PRESIDENCIAL
DIRECTIVE/HSPD-20, y la Alianza
Internacional sobre la Gripe
Aviar y Pandémica.
Los acusados han planeado el
asesinato en masa de la
población de los EE.UU por medio
de la administración de vacunas,
pero también mediante la
instalación de una amplia red de
campos de concentración del FEMA
y la identificación de fosas
comunes. Los acusados han
participado en la elaboración y
aplicación de un plan de golpe
de Estado contra los Estados
Unidos de América, utilizando la
peste porcina o la gripe
pandémica como pretexto. Dicho
sindicato del crimen emplea la
delincuencia internacional,
utilizando a las Naciones Unidas
y la Organización Mundial de la
Salud como frente, en violación
de todas las leyes sobre alta
traición.
Se presentan pruebas de que el
complejo de las empresas
farmacéuticas de Baxter,
Novartis y Sanofi
Aventis, son parte de una
organización que opera de fuera
de Estados Unidos en base a un
doble propósito de armas
biológicas, programa financiado
por el sindicato penal
internacional y diseñado para la
aplicación de los asesinatos en
masa para reducir la población
del mundo en los próximos diez
años, a sembrar el terror, para
justificar la obligación de que
los ciudadanos renuncien
voluntariamente a sus derechos y
se sometan a las normas de
cuarentena en los campos de FEMA.
Asimismo, los activos
patrimoniales, las casas,
empresas, granjas, de los que
morirán por culpa de este plan
de este sindicato de la
delincuencia internacional
quedarán a la disposición de
ellos. Al eliminar la población
de América del Norte, la élite
internacional tendrá acceso a
los recursos naturales de la
región y mediante la eliminación
de los Estados Unidos y su
constitución democrática al
unificar, bajo la entidad de un
superestado en America del
Norte, con una moneda
internacional, el grupo de
delincuencia tendrá el control
total de América del Norte.
La pandemia también ha sido
diseñada por el mismo grupo de
delincuencia internacional con
objeto de distraer la atención
del mundo de la devastadora
crisis económica mundial,
marcada por la pobreza, el
colapso económico, la guerra, la
pérdida de los derechos civiles
y la desaparición de programas
sociales del Estado.
En la denuncia se presentan:
El modelo de Estado de
Emergencia de Salud Ley de
poderes, el Consejo Nacional de
Seguridad DIRECTIVA PRESIDENCIAL
/ NSPD 51 y SEGURIDAD
PRESIDENCIAL DIRECTIVE/HSPD-20 y
otras leyes de emergencia,
cuarentena, indemnizaciones en
caso de muerte o lesiones por
vacuna, vacunación de
emergencia, obligatoriedad de
vacunas, ley marcial, emergencia
nacional, suspensión de
gobierno, obligatoriedad de los
médicos de vacunar, eliminación
de obligación de indemnización
de los Estados en caso de muerte
o lesión por vacuna,
militarización de la gestión de
emergencias sanitarias, se
priman las decisiones de las
organizaciones mundiales en la
salud (como la OMS) frente a las
del Gobierno de los Estados
Unidos, ejercicios de
preparación de Northcom frente a
la pandemia, aprobación de
legislación para facultar el
estado de vigilancia y control
de sus ciudadanos en caso de
pandemia, aprobación de
directivas que otorgan plenos
poderes para el presidente en
caso de evento catastrófico,
entre otras leyes aprobadas.
Source:http://www.pandemicflu.gov/plan/states/stateplans.html
Otros hechos presentados
En septiembre de 2005, el Dr.
David Nabarro fue nombrado el
primer coordinador de la gripe
del sistema de la ONU. El 29 de
septiembre de 2005, en una
conferencia de prensa en las
Naciones Unidas, Nabarro dejó
claro que su trabajo consistía
en preparar para el virus H5N1,
conocido como la gripe aviar. Se
cuantificó la mortalidad que se
esperaba de la siguiente manera:
"No estoy, en el momento, en la
libertad de darle una predicción
sobre el número, pero sólo
quiero hacer hincapié en que,
digamos, la serie de muertes
podría ser cualquier cosa desde
5 a 150 millones de personas. "
Varios organismos dentro del
Departamento de Salud y
Servicios Humanos (DHHS), entre
ellas la Oficina del Secretario,
la Food and Drug Administration
(FDA), los CDC y el Instituto
Nacional de Alergias y
Enfermedades Infecciosas (NIAID),
están en el proceso de trabajo
con los fabricantes de vacunas a
fin de facilitar la producción
de los lotes de vacunas
experimentales para los dos
cepas H5N1 y H9N2, así como la
contratación de la fabricación
de 2 millones de dosis de una
vacuna contra el H5N1.
El 27 de octubre de 2005, el
Departamento de Salud y
Servicios Humanos otorgó un
contrato de $ 62.5 millones a
Chiron Corporation para la
fabricación de una vacuna contra
la gripe aviar destinada a
proteger contra la cepa H5N1 del
virus de la gripe. Esto siguió a
una anterior otorgó $ 100
millones del contrato-a Sanofi
Pasteur, el negocio de las
vacunas Sanofi-Aventis Group,
para la vacuna contra la gripe
aviar.
Según The New York Times en
marzo de 2006, "los gobiernos de
todo el mundo han gastado miles
de millones de planificación
para una posible pandemia de
influenza: la compra de
medicamentos, ejecutando
simulacros de desastres, [y] el
desarrollo de estrategias para
reforzar los controles en las
fronteras", debido a la amenaza
que el virus H5N1. [83]
El 1 de noviembre de 2005 el
Presidente Bush presentó una
solicitud al Congreso por valor
de:
$ 7.1 millones para iniciar la
aplicación de la Estrategia
Nacional de salvaguardia contra
el peligro de pandemia de gripe.
La solicitud incluye $ 251
millones para detectar y
contener brotes antes de que se
extiendan en todo el mundo;
$ 2,8 millones para acelerar el
desarrollo de la cultura de la
tecnología celular, $ 800
millones para el desarrollo de
nuevos tratamientos y vacunas,
$ 1,519 millones para los
departamentos de Salud y
Servicios Humanos (HHS ) y de
Defensa para la compra de las
vacunas contra la gripe,
$ 1.029 millones para almacenar
medicamentos antivirales, y
$ 644 millones para garantizar
que todos los niveles de
gobierno están preparados para
responder a un brote pandémico.
[96]
=======================================================================
13.) Farmacéuticas, las
ganadoras frente a la influenza
=======================================================================
Source:http://eleconomista.com.mx/negocios/2009/09/01/farmaceuticas-las-ganadoras-frente-influenza
1 Septiembre, 2009 - 16:55
Los laboratorios farmacéuticos
son por ahora los grandes
beneficiarios de la pandemia de
la influenza, ya que los
antivirales les están redituando
enormes sumas, al menos hasta
que las vacunas estén listas
para su comercialización.
Desde abril pasado, cuando
apareció el virus de influenza A
H1N1, los gobiernos han
desbloqueado fondos masivos para
proteger a sus poblaciones con
antivirales, ya que son el único
tratamiento efectivo, refirió un
reporte especial del diario
francés Le Monde.
Apenas la semana pasada, España
declaró que invertiría 333
millones de euros (U$473
millones) para luchar contra la
influenza humana, mientras
Francia estimó su plan en 1,000
millones de euros(U$1,400
millones) entre vacunas y
antivirales.
El laboratorio británico
GlaxoSmithKline (GSK), el
francés Sanofi Pasteur y los
suizos Novartis y Roche
'aparecen, por ahora, como los
principales beneficiarios de la
pandemia por los antivirales',
dijo el analista Jean-Jacques Le
Fur, de la sociedad Bourse Oddo.
Más de 200 millones de dosis del
Tamiflu han sido solicitados por
85 países desde abril pasado,
'la venta de esta droga se
multiplicó por 12 respecto al
mismo periodo del 2008', indicó
Thierry Verrecchia, analista de
la Sociedad de Inversión Raymond
James Euro Equities.
Aunque Roche -que tiene la
patente de este antiviral- ha
hecho descuentos en ventas a los
gobiernos, la rentabilidad de
Tamiflu sigue siendo cómoda. 'Su
margen bruto es del 40%,
mientras la de la vacuna contra
la influenza A se aproxima a 15
por ciento'.
Ante tal panorama, se prevé que
las ventas del antiviral deberán
generar un volumen de negocios
de más de 1,300 millones de
euros (U$1,800 millones) en el
2009, es decir 4.2% de las
ventas de Roche.
Sin embargo, este éxito tiene un
impacto limitado en las cuentas
del grupo suizo, porque debe
pagar una parte de los
beneficios de Tamiflu al
estadunidense Gilead,
descubridor de la molécula.
Respecto a las ventas del
antiviral Relenza, el impacto a
las cuentas de GSK será aún más
diluida, ya que este medicamento
había sido prácticamente
abandonado y apenas se comenzó
su lanzamiento comercial.
Ahora, para los fabricantes de
vacunas la pandemia 'no será un
muy buen negocio', indicó Le
Monde.
'La creación de una vacuna en
tan poco tiempo es una tarea más
difícil -y mucho menos rentable-
que producir antivirales',
agregó.
Desde el brote del virus A H1N1,
más de mil millones de dosis de
vacunas han sido ordenados por
el hemisferio norte por cerca de
10 millones de euros, pero la
competencia entre los
productores pesan sobre los
márgenes.
El laboratorio Sinovac China,
uno de los pocos en desarrollar
un tratamiento contra la
influenza humana en una sola
inyección, anunció que su
producto sería 30% más barato
que sus competidores.
RDS/doch
=======================================================================
14.) Big Pharma: Baxter Files
Swine Flu Vaccine Patent a Year
Ahead of Outbreak
=======================================================================
Source:Http:///www.globalresearch.ca/index.php?context=va&aid=14430/
Barack Opharma issues the
ultimate bad news during his
weekly Friday night bad news
dump: Legal immunity set for
swine flu vaccine makers 17 Jul
2009 The last time the
government embarked on a major
vaccine campaign against a new
swine flu, thousands filed
claims contending they suffered
side effects [paralysis, death]
from the shots. This time, the
government has already taken
steps to head that off. Vaccine
makers and federal officials
will be immune from lawsuits
that result from any new swine
flu vaccine, under a document
signed by Secretary of Health
and Human Services Kathleen
Sebelius, government health
officials said Friday. The
document signed by Sebelius last
month grants immunity to those
making a swine flu vaccine,
under the provisions of a 2006
law for public health
emergencies.
Baxter Files Swine Flu Vaccine
Patent a Year Ahead of Outbreak
--US20090060950A1 to Baxter
International filed 28th August
2008 By Lara 10 Jul 2009 Baxter
Vaccine Patent Application US
2009/0060950 A1 --'In particular
preferred embodiments the
composition or vaccine comprises
more than one antigen.....such
as influenza A and influenza B
in particular selected from of
one or more of the human H1N1,
H2N2, H3N2, H5N1, H7N7, H1N2,
H9N2, H7N2, H7N3, H10N7
subtypes, of the pig flu H1N1,
H1N2, H3N1 and H3N2 subtypes, of
the dog or horse flu H7N7, H3N8
subtypes or of the avian H5N1,
H7N2, H1N7, H7N3, H13N6, H5N9,
H11N6, H3N8, H9N2, H5N2, H4N8,
H10N7, H2N2, H8N4, H14N5, H6N5,
H12N5 subtypes.'
Baxter can take no more H1N1 flu
vaccine orders 16 Jul 2009 While
at least 50 governments have
placed orders or are negotiating
with drug companies for supplies
of flu vaccine against the
[their] fast spreading H1N1
strain, the lone U.S.-based
maker has already taken on as
much as it can handle.
Baxter International Inc said on
Thursday it has taken orders
from five countries, including
Britain, Ireland and New Zealand,
for a total of 80 million doses
of H1N1 vaccine and will not
take any more.
'Clearly we believe this demand
has the potential to translate
into a significant opportunity.'
Baxter 2Q Profit Up 7.9%; Full-Year
Guidance Raised 16 Jul 2009
Baxter International Inc. posted
a stronger-than-expected 7.9%
rise in second-quarter profit
with help from improved margins
and product sales that continued
to avoid any hits from the
economic downturn. The medical-products
maker boosted its 2009 earnings
guidance while saying the
increase doesn't reflect at this
point any contribution from
making a vaccine for the H1N1
flu strain. Baxter reported a
second-quarter profit of $587
million, or 96 cents a share, up
from $544 million, or 85 cents a
share, a year earlier.
Baxter working on vaccine to
stop swine flu, though admitted
sending live pandemic flu
viruses to subcontractor By Lori
Price 26 Apr 2009 The OMFG
moment of the century:
Illinois-based Baxter working on
vaccine to 'stop' swine flu
outbreak in Mexico 25 Apr 2009
Specialty drug maker Baxter
International Inc. will work
with the World Health
Organization to develop a
vaccine that could stem [foment]
an outbreak of a deadly swine
flu strain in Mexico. Baxter
spokesman Christopher Bona said
Saturday that the Deerfield,
Ill.-based company has asked the
WHO for a sample of the flu
strain. He says Baxter has
patented technology that allows
the company to develop vaccines
in half the time it usually
takes -- about 13 weeks instead
of 26.
Baxter admits sending live avian
flu viruses to subcontractor
--Baxter admits contaminated
seasonal flu product contained
live bird flu virus 27 Feb 2009
The company that released
contaminated flu virus material
from a plant in Austria
confirmed Friday that the
experimental product contained
live H5N1 avian flu viruses. And
an official of the World Health
Organization's European
operation said the body is
closely monitoring the
investigation into the events
that took place at Baxter
International's research
facility in Orth-Donau,
Austria.
Human trial of swine flu vaccine
'soon' 15 Jul 2009 The federal
government has defended its
policy of not following the
United Kingdom's lead and
rushing out a swine flu vaccine.
Biopharmaceutical company CSL
will start clinical vaccine
trials on 240 healthy adults in
Adelaide next week. The vaccine
is due to be rolled out in
October.
CLG Pandemic Action Alerts 12
Jul 2009 Petition against
mandatory vaccines; contact the
White House, US Congress --More
flu news here
=======================================================================
15.) AstraZeneca compra la
estadounidense Medimmune por mas
de 11.000 millones de euros
=======================================================================
Source:www.eleconomista.es/empresas-finanzas/noticias/201934/04/07/Astra-Zeneca-compra-estadounidense-Medimmune-por-mas-11000-millones-euros.html
Copenhague, 23 abr (EFECOM).- La
farmacéutica sueco-británica
Astra Zeneca anunció hoy que ha
cerrado un acuerdo con la
estadounidense Medimmune para
adquirir la totalidad de sus
acciones por 15.600 millones de
dólares, lo que supone un pago
de 58 dólares por acción.
La operación, que se espera esté
completada en junio, cuenta con
el apoyo de la dirección de
Medimmune, que ha recomendado a
sus accionistas que acepten la
oferta, según un comunicado de
Astra Zeneca.
La compañía estadounidense
obtuvo en 2006 unos ingresos de
1.300 millones dólares y unas
ganancias antes de impuestos de
75 millones, cuenta con 2.500
empleados y tiene su sede
central en Maryland (Estados
Unidos).
Medimmune trabaja
fundamentalmente en tres áreas
de investigación: enfermedades
infecciosas, cáncer y
enfermedades inflamatorias.
El director general de la firma
sueco-británica, David Brennan,
señaló en el comunicado que la
compra permitiría a la compañía
diversificar su capacidad de
investigación y aumentar sus
posibilidades de crecimiento.
Astra Zeneca anunció hoy también
unos beneficios brutos de 2.267
millones de dólares en el primer
trimestre, un 2,5 por ciento más
que en el mismo período de
2006.EFECOM
Copenhague, 23 abr (EFECOM).- La
farmacéutica sueco-británica
Astra Zeneca anunció hoy que ha
cerrado un acuerdo con la
estadounidense Medimmune para
adquirir la totalidad de sus
acciones por 15.600 millones de
dólares, lo que supone un pago
de 58 dólares por acción.
La operación, que se espera esté
completada en junio, cuenta con
el apoyo de la dirección de
Medimmune, que ha recomendado a
sus accionistas que acepten la
oferta, según un comunicado de
Astra Zeneca.
La compañía estadounidense
obtuvo en 2006 unos ingresos de
1.300 millones dólares y unas
ganancias antes de impuestos de
75 millones, cuenta con 2.500
empleados y tiene su sede
central en Maryland (Estados
Unidos).
Medimmune trabaja
fundamentalmente en tres áreas
de investigación: enfermedades
infecciosas, cáncer y
enfermedades inflamatorias.
El director general de la firma
sueco-británica, David Brennan,
señaló en el comunicado que la
compra permitiría a la compañía
diversificar su capacidad de
investigación y aumentar sus
posibilidades de crecimiento.
Astra Zeneca anunció hoy también
unos beneficios brutos de 2.267
millones de dólares en el primer
trimestre, un 2,5 por ciento más
que en el mismo período de
2006.EFECOM
alc/rz/jj
========================================================================
16.) Dos mutaciones hacen
letal al H5N1
========================================================================
Source:http://axxon.com.ar/not/168/c-1680102.htm
Dos mutaciones bastan para que
el relativamente inocuo virus
H5N1, el causante de la gripe
aviar, se convierta en un agente
letal en más del 50% de los
casos de las infecciones en
personas.
Ésta es la conclusión a la que
han llegado los investigadores
de la Universidad de Tokio al
comparar las proteínas de la
cubierta del virus en muestras
tomadas de aves silvestres y de
enfermos por la enfermedad. El
descubrimiento fue publicado en
la revista Nature.
Dos cambios en una proteína
Los dos cambios se dan en la
proteína hemaglutinina (la "H"
del nombre del virus). Gracias a
ellos, el virus adquiere la
propiedad de unirse más
fácilmente a las células que
forman las paredes internas del
sistema respiratorio.
Así es como comienza el proceso
de infección, que acaba con un
deterioro que puede llevar a la
muerte.
Los investigadores, dirigidos
por Yoshihiro Kawaoka, han
detectado los cambios (una
sencilla alteración en un
aminoácido, el eslabón que forma
la cadena que es toda proteína)
por separado. Es decir, no
tienen que coincidir los dos
para que el virus sea más
peligroso para las personas.
La siguiente pregunta es qué
pasará si ambos cambios
coincidieran.
Hasta ahora, por culpa de estos
cambios y probablemente otros
factores todavía no
descubiertos, la gripe aviar se
ha cobrado 153 víctimas
mortales, y ha hecho enfermar a
otras 105 personas, según el
último recuento de la
Organización Mundial de Salud
(OMS).
La última de ellas, una mujer
indonesia que falleció el pasado
13 de noviembre.
El hallazgo no se refiere a
estos casos, pero indica el
camino que debe recorrer el
virus hasta llegar a ser la
pandemia que temen los
expertos.
Fuente: Univisión. Aportado por
Eduardo J. Carletti
</!C
El doctor Wellington Sun de la FDA
dijo en el encuentro que la agencia
autorizaría la nueva vacuna H1N1
como un cambio de cepa -como sucede
con las nuevas formulaciones de la
vacuna estacional cada año- a
diferencia de hacerlo como si se
tratara de una inmunización
completamente nueva. Esto aceleraría
la aprobación.
=======================================================================
17.) VACUNA H1N1: Múltiples
efectos secundarios en Suecia
por Pandemrix (GSK) y en Suiza
entran grandes dudas
======================================================================
Source:http://notemaslaverdad.wordpress.com/2009/10/22/vacuna-h1n1-multiples-efectos-secundarios-en-suecia-por-pandemrix-gsk-y-en-suiza-entran-grandes-dudas/
Publicado por notemaslaverdad en
22 Octubre 2009
Las autoridades gubernamentales
de Suiza han cambiado sus
directrices para la vacunación
de mujeres embarazadas y niños
pequeños y se recomienda una
vacuna sin adyuvantes, según
informaciones en el diario
Tages-Anzeiger.
Joachim Gross, de la
reglamentación farmacéutica
suiza, Swissmedic, dijo: “Porque
no hay suficientes datos
clínicos de las vacunas,
especialmente para los niños y
las mujeres embarazadas, daremos
recomendaciones de vacunación
concretas.”
Jefe médico Pietro Vernazza del
Cantón Hospital St. Gallen se
inyectó con el adyuvante AS03 de
GSK como parte de un estudio,
dijo: “Se puede sentir eso. El
brazo me duele. Es difícil
dormir por la noche. En algunos
casos puede haber fiebre.
Algunas personas pueden tener
dificultades de movilidad
durante algunos días. “
La decisión del gobierno suizo a
abandonar los adyuvantes en
vacunas de la gripe porcina para
las mujeres embarazadas y niños
pequeños, se produce en medio de
una tormenta de protestas en
Alemania en el uso de los
ingredientes probados y tóxicos,
con el pretexto de una
emergencia pandémica.
Por otro lado, después de
iniciar la vacunación contra el
H1N1 en Suecia, se han dado casi
200 casos con efectos
secundarios reseñables.
Oficialmente a día de ayer
habían sido reportados 140 casos
de efectos secundarios a las
autoridades sanitarias Suecas.
Entre ellas la Muerte de una
persona debida a un ataque
cardiaco, aunque dichas
autoridades aseguran que no está
demostrado que haya sido debida
a la vacuna.
Aun así, Annika Linde, director
del Instituto Sueco para el
Control de Enfermedades
Infecciosas (SMI) se las arregla
para darle a esto giro en algo
positivo al afirmar que “La
vacuna tiene más efectos
secundarios de la vacuna contra
la gripe normal. Es una señal
que demuestra que se da una
protección efectiva”. Digo yo
que la que tenía que haber
muerto era ella.
Miles de suecos han sido
vacunados hasta la fecha y los
informes de los efectos
secundarios están inundando al
Instituto Sueco para el Control
de Enfermedades Infecciosas (SMI).
Annika Linde: “Es obvio que la
vacuna contra la gripe porcina
en los resultados tienen más
efectos secundarios que las
vacunas contra la gripe normal.
Eso es porque la vacuna contra
la gripe porcina contiene
adyuvantes, aceite de hígado de
tiburón, lo que provoca la
respuesta de defensa del sistema
inmunitario. También resultados
en la protección contra el virus
se vuelve mejor “.
Varios casos graves de
reacciones alérgicas son
reportados a la unidad para la
seguridad de medicamentos.
“Hasta ahora los efectos
secundarios observados no son
inesperados”, dice Gunilla
Sjölin Forsberg. Esta unidad ya
ha solicitado a algunas de las
muchas unidades de vacunación
que informen sobre efectos
secundarios para conseguir un
mejor control sobre la situación.
Esta afirmación es sorprendente
ya que, según la práctica
habitual, todos los efectos
secundarios deben ser
automáticamente notificados – ¿verdad?
“Enfermé con la vacuna”- Hälsa –
Expressen.se
Una enfermera a la que le fue
administrada la vacuna la semana
pasada hoy miércoles se siente
todavía enferma. Se levantó con
fiebre alta y escalofríos al día
siguiente de tomar la vacuna de
influenza porcina. “Estaba
temblando en mi cuerpo. Sin
fuerzas, hasta el punto de que
ni siquiera podía sostener un
vaso de agua en la mano.”, Lotta
Lindström, dice.”- Ahora estoy
pensando en qué es lo que nos
han inyectado. Realmente estoy
muy afectada. Es una sensación
muy desagradable”.
María, 27: “Me hizo un terrible
daño” – Hälsa – Expressen.se
María Strindlund no está segura
de haber hecho la elección
correcta al decidir tomar la
vacuna. Ella también tiene una
fiebre alta y escalofríos. “-
Desde que trabajo como enfermera,
decidí que era la mejor cosa que
podía hacer.”, Dice ella. “Al
principio no sentía nada, pero
unas horas después los efectos
secundarios comenzaron a
afectarme”. “- Tengo un dolor
extremo en el brazo. Ya no lo
puedo levantar”. Le vino la
fiebre y los escalofríos. “_ Yo
estaba acostada en la cama
temblando y sentía mucho frío y
estaba en una ducha de agua
caliente para entrar en calor.”
Ella dice que muchos colegas
suyos de los que también tomaron
la vacuna ha tenido reacciones
similares. Ella ha estado
tomando muchas vacunas en el
pasado sin ninguna reacción de
ningún tipo.
Rebecka, 32: “me siento
decrépita” – Hälsa –
Expressen.se
Rebecka Andersson fue la primera
persona que recibió la vacuna en
Suecia. Ella se le sobrevino la
fiebre y se sentía mal del
estómago después de tomar la
vacuna. “- He perdido toda la
energía”, dice ella. “Nunca
estoy enferma, por lo que
normalmente se entiende que debe
ser la vacuna”. Sus compañeros
de clase fueron vacunados, al
mismo tiempo y se afirma que
cinco de los diecinueve también
se enfermaron con la vacuna
contra la gripe porcina.
Lotta, 49: “No puedo dormir” –
Hälsa – Expressen.se
Lotta Lindström, una enfermera,
afirma que recibió la vacuna
hace una semana y aún no está
bien. “- Esto es muy preocupante”,
dice ella. “- No he dormido nada
la noche después de la inyección
ya que el dolor en mi brazo era
muy grave.” El día después, en
el trabajo, la fiebre del vino.
Más tarde tuvo dolores de cabeza.
Todavía hoy, una semana después
de la inyección se siente
enferma.
Otra enfermera, Jennely, casi no
podía caminar cinco metros
después de que ella se enfermó
con la vacuna de la gripe
porcina. Estaba completamente
sana cuando se puso la vacuna,
pero el día después tenía 39
grados de fiebre (102,2 F). “-
Yo casi no podía caminar los
cinco metros que tenía al baño”,
dice ella. La fiebre duró tres
días. Varios de sus compañeros
en el trabajo han tenido
experiencias similares. “- Yo sé
de al menos diez que tienen
fiebre, estamos cerca de 80
personas en mi lugar de trabajo.”
===========================================================================
Other Sources: Autism
prevention. blogspot.com
===========================================================================
It is very possible that
PATERNAL AGE is the major
predictor of(non-familial)
autism." Harry Fisch, M.D.,
author "The Male Biological
Clock". Sperm DNA mutates and
autism, schizophrenia bipolar
etc. results. What is the
connection with autoimmune
disorders? Having Type 1
diabetes, SLE,etc. in the
family, also if mother had older
father. NW Cryobank will not
accept a sperm donor past 35th
BD to minimize genetic
abnormalities.VACCINATIONS also
cause autism.
Fuente: http://autism-prevention.blogspot.com/
=======================================================================
18.) Fort Detrick Inventory
Turns Up 9,220 More Vials of
Pathogens
========================================================================
Source:http://www.washingtonpost.com/wp-dyn/content/article/2009/06/17/AR2009061703271.html
Washington Post Staff Writer
An inventory of potentially
deadly pathogens at Fort
Detrick's infectious disease
laboratory found more than 9,000
vials that had not been
accounted for, Army officials
said yesterday, raising concerns
that officials wouldn't know
whether dangerous toxins were
missing.
After four months of searching
about 335 freezers and
refrigerators at the U.S. Army
Medical Research Institute of
Infectious Diseases in
Frederick, investigators found
9,220 samples that hadn't been
included in a database of about
66,000 items listed as of
February, said Col. Mark
Kortepeter, the institute's
deputy commander.
The vials contained some
dangerous pathogens, among them
the Ebola virus, anthrax
bacteria and botulinum toxin,
and less lethal agents such as
Venezuelan equine encephalitis
virus and the bacterium that
causes tularemia. Most of them,
forgotten inside freezer
drawers, hadn't been used in
years or even decades. Officials
said some serum samples from
hemorrhagic fever patients dated
to the Korean War.
Kortepeter likened the inventory
to cleaning out the attic and
said he knew of no plans for an
investigation into how the vials
had been left out of the
database. "The vast majority of
these samples were working stock
that were accumulated over
decades," he said, left there by
scientists who had retired or
left the institute.
"I can't say that nothing did
[leave the lab], but I can say
that we think it's extremely
unlikely," Kortepeter said.
Still, the overstock and the
previous inaccuracy of the
database raised the possibility
that someone could have taken a
sample outside the lab with no
way for officials to know
something was missing.
"Nine thousand, two hundred
undocumented samples is an
extraordinarily serious breach,"
said Richard H. Ebright, a
professor at Rutgers University
who follows biosecurity. "A
small number would be a concern;
9,200 . . . at an institution
that has been the focus of
intense scrutiny on this issue,
that's deeply worrisome.
Unacceptable."
The institute has been under
pressure to tighten security in
the wake of the 2001 anthrax
attacks, which killed five
people and sickened 17. FBI
investigators say they think the
anthrax strain used in the
attacks originated at the Army
lab, and its prime suspect,
Bruce E. Ivins, researched
anthrax there. Ivins committed
suicide last year during an
investigation into his
activities.
Kortepeter noted that since 2001
the lab has imposed multiple
layers of security to check
people entering and leaving,
that there are now cameras in
the labs, and that employees are
subjected to a reliability
program and random inspections.
"The bottom line is, we have a
lot of buffers to prevent
anybody who shouldn't be getting
into the laboratory," Kortepeter
said.
Sam Edwin, the institute's
inventory control officer, said
most of the samples found were
vials with tiny amounts of
pathogens that would thaw
quickly and die once they were
taken out of a freezer, making
smuggling something off the base
difficult.
The probe began in February,
when a problem accounting for
Venezuelan equine encephalitis
virus triggered the suspension
of most research at the lab. A
spot check in January found 20
samples of the virus in a box of
vials instead of the 16 listed
in the institute's database.
Most work was stopped until the
institute could take a thorough
inventory of its stock of
viruses and bacteria.
Edwin said about 50 percent of
the samples that had been found
were destroyed. The rest were
added to the catalog. Because
the lab will now conduct an
inventory every year, "it's
really less likely that we will
be in a situation like this
again," he said.
Procedures have changed, too.
Scientists who have worked at
the lab said that in the past,
departing scientists turned over
their logbooks to their
successors, but records were
sometimes incomplete or complex.
As generations of scientists
passed through, the knowledge of
what was in the freezers was
lost. With a comprehensive
database, every sample is now
tracked until it is destroyed or
transferred.
But some scientists are
skeptical. Unlike uranium or
chemical weapons, pathogens are
living materials that can
replicate and die. A small
amount can easily be turned into
a large amount. They said the
strict inventories slow their
work without guaranteeing
security.
======================================================================
19.) French scientists sound
the alarm about aluminum in
vaccines — crickets from media
and health authorities
======================================================================
Source:https://medium.com/@jbhandley/french-scientists-sound-the-alarm-about-aluminum-in-vaccines-crickets-from-media-and-health-d3fc0fe23079
BY J.B. HANDLEY September 9,
2017
“In the context of massive
development of vaccine-based
strategies worldwide, the
present study may suggest that
aluminium adjuvant
toxicokinetics and safety
require reevaluation.”
Maybe it will just go away?
PARIS, France — Roman K.
Gherardi and his colleagues from
the Université Paris Est Créteil
(“UPEC”)in France issued a
worldwide warning in late 2016
about the aluminum adjuvant used
in childhood vaccines. Their
paper, published in the
highly-respected journal
Toxicology, is deeply distrubing
for any parent contemplating
vaccinating their child
according to the present
schedule recommended by the
American Centers for Disease
Control (“CDC”). And, it’s
highly likely that this is the
first time you’ve ever heard
about it.
It’s safe to say that this
study’s conclusions have
revolutionized our understanding
of aluminum adjuvant, the kind
used in most children’s
vaccines.
The French study authors were
very concerned about the
widespread use of aluminum
adjuvant:
“Concerns about its [aluminum
adjuvant’s] safety emerged
following recognition of its
unexpectedly long-lasting
biopersistence within immune
cells in some individuals, and
reports of chronic fatigue
syndrome, cognitive dysfunction,
myalgia, dysautonomia and
autoimmune/inflammatory features
temporally linked to multiple
Al-containing vaccine
administrations.”
The scientists also discovered,
through mouse-models, a deeply
alarming unique characteristic
of aluminum adjuvant: low,
consistent doses (the kind given
to babies through their
vaccines) were MORE neurotoxic
than a single bolus dose:
“We conclude that Alhydrogel
[aluminum adjuvant] injected at
low dose in mouse muscle may
selectively induce long-term Al
cerebral accumulation and
neurotoxic effects. To explain
this unexpected result, an
avenue that could be explored in
the future relates to the
adjuvant size since the injected
suspensions corresponding to the
lowest dose, but not to the
highest doses, exclusively
contained small agglomerates in
the bacteria-size range known to
favour capture and, presumably,
transportation by monocyte-lineage
cells. In any event, the view
that Alhydrogel neurotoxicity
obeys ‘the dose makes the
poison’ rule of classical
chemical toxicity appears overly
simplistic.”
This is a confusing conclusion,
but profoundly important, here’s
a further explanation from the
excellent website, Vaccine
Papers.org:
A new paper (Crepeaux et al.) by
the Gherardi research group in
France reports important results
on the toxicity and transport of
aluminum (Al) adjuvant in mice.
This single study is especially
valuable because it looked at
many outcomes: behavioral
effects, immune (microglial)
activation in the brain, and Al
transport into the brain. The
study tested dosages of 200 ,
400 and 800 mcg/Kg, injected
intramuscularly (IM). The Al
adjuvant used was AlOH (brand
name Alhydrogel), the most
common vaccine adjuvant in use
today. It is used in the
tetanus, Hep A, Hep B, HiB,
pneumococcal, meningococcal, and
anthrax vaccines.
Remarkably, the study found that
the lowest dosage (200 mcg/Kg)
was the most toxic! For many
outcomes, the 400 and 800 mcg/Kg
dosages had no observable
adverse effects, but the 200
mcg/Kg dosage did.
The low toxicity of the higher
dosages appears to be a
consequence of dosage-dependent
inflammation at the injection
site. The high dosages caused
intense inflammation at the
injection site, forming “granulomas”.
The 200 mcg/Kg dosage did not
produce granulomas. Granulomas
are hard nodules in tissue
produced in response to injury,
infection or foreign substances.
Its a way the body “walls off”
injured tissue and prevents the
spread of infection or toxins.
The granuloma appears to provide
protection from Al adjuvant
toxicity; apparently the
granuloma prevented Al adjuvant
particles from leaving the
injection site. This explains
why the 200 mcg/Kg dosage
affected the brain and behavior,
while the higher dosages did
not. This suggests that it is
more dangerous and harmful to
administer numerous small
injections of Al adjuvant,
compared to a large single
injection capable of inducing a
granuloma.
The study authors also disputed
the way the FDA and CDC
currently think about aluminum
adjuvant toxicity, basically
saying that the current research
approach is wrong:
“As a possible consequence,
comparing vaccine adjuvant
exposure to other non- relevant
aluminium exposures, e.g.
soluble aluminium and other
routes of exposure, may not
represent valid approaches.”
And, the French scientists
finish with a conclusion that
all parents should find very
troubling:
“In the context of massive
development of vaccine-based
strategies worldwide, the
present study may suggest that
aluminium adjuvant
toxicokinetics and safety
require reevaluation.”
Radio Silence
Where’s the media? Where’s the
CDC? Where are the other member
of our public health
authorities? Where are the
elected officials? Where’s the
American Academy of Pediatrics?
Why is no one willing to discuss
a highly credible study raising
grave concerns about something
being injected into American
babies? Moreover, the scientists
directly challenge the CDC’s
approach to assessing the safety
of injected aluminum adjuvant,
basically saying it’s being done
incorrectly.
For further reading on this
complex topic, I hope you’ll
consider reading a more
extensive exploration of the
complex relationship between
aluminum adjuvant and autism,
which has so far has more than
250,000 reads:
“Scientists appear to be far
closer to explaining the
mechanisms of action within the
body that cause autism. Most of
the research that has created
this understanding has been
published in the last 36 months,
and largely from international
scientists in Canada, France,
Israel, and China. Four clear,
replicable, and related
discoveries explaining how
autism is triggered are forming
an undeniably clear picture of
autism’s causation, and possibly
ways to alleviate the symptoms,
too.”
Did Chinese scientists find
autism’s missing puzzle piece?
BY J.B. HANDLEY February 22,
2017
healthcareinamerica.us
J.B. Handley is the father of a
child with Autism. He and his
wife co-founded Generation
Rescue, Jenny McCarthy’s autism
charity. He spent his career in
the private equity industry and
received his undergraduate
degree with honors from Stanford
University. He is also the
author of “The Only Vaccine
Guide a New Parent Will Ever
Need” , “An Angry Father’s Guide
to Vaccine-Autism Science”, and
“7 reasons CDC employees should
be “crying in the hallways” Mr.
Handley has started a podcast
called “How to End the Autism
Epidemic” — you might enjoy his
first six interviews:
=================================================================
20.) Influenza vaccination
and Guillain Barre syndrome
small star, filled.
=================================================================
Geier MR, Geier DA, Zahalsky AC.
The Genetic Centers of America,
14 Redgate Court, Silver Spring,
MD 20905, USA. [email protected]
<[email protected]>
Comment in:
· Clin Immunol. 2003
Dec;109(3):359; author reply
360-1.
Acute and severe Guillain Barre
Syndrome (GBS) cases reported
following influenza vaccine to
the Vaccine Adverse Events
Reporting System (VAERS)
database from 1991 through 1999
were examined. Endotoxin
concentrations were measured
using the Limulus amebocyte
lysate assay in influenza
vaccines. There were a total of
382 cases of GBS reported to the
VAERS database following
influenza vaccination
(male/female ratio, 1.2). The
median onset of GBS following
influenza vaccine was 12 days (interquartile
range, 7 days to 21 days). There
was an increased risk of acute
GBS (relative risk, 4.3; 95%
confidence interval, 3.0 to 6.4)
and severe GBS (relative risk,
8.5; 95% confidence interval,
3.7 to 18.9) in comparison to an
adult tetanus-diphtheria (Td)
vaccine control group. There
were maximums in the incidence
of GBS following influenza
vaccine that occurred
approximately every third year
(1993, 1996, and 1998) and
statistically significant
variation in the incidence of
GBS among different influenza
manufacturers. Influenza
vaccines contained from a 125-
to a 1250-fold increase in
endotoxin concentrations in
comparison to an adult Td
vaccine control and endotoxin
concentrations varied up to
10-fold among different lots and
manufacturers of influenza
vaccine. The biologic mechanism
for GBS following influenza
vaccine may involve the
synergistic effects of endotoxin
and vaccine-induced
autoimmunity. There were minimal
potential reporting biases in
the data reported to the VAERS
database in this study. Patients
should make an informed consent
decision on whether to take this
optional vaccine based upon its
safety and efficacy and
physicians should vigilantly
report GBS following influenza
vaccination to the VAERS in the
United States so that continued
evaluation of the safety of
influenza vaccine may be
undertaken.
=======================================================================
21.) Guillain-Barré syndrome
following influenza vaccination.
=======================================================================
JAMA. 2004 Nov
24;292(20):2478-81
Haber P, DeStefano F, Angulo FJ,
Iskander J, Shadomy SV,
Weintraub E, Chen RT.
Immunization Safety Branch,
Epidemiology and Surveillance
Division, National Immunization
Program, Centers for Disease
Control and Prevention, Atlanta,
Ga 30333, USA. [email protected]
CONTEXT: An unexplained increase
in the risk of Guillain-Barre
syndrome (GBS) occurred among
recipients of the swine
influenza vaccine in 1976-1977.
Guillain-Barre syndrome remains
the most frequent neurological
condition reported after
influenza vaccination to the
Vaccine Adverse Events Reporting
System (VAERS) since its
inception in 1990. OBJECTIVE: To
evaluate trends of reports to
VAERS of GBS following influenza
vaccination in adults. DESIGN,
SETTING, AND PARTICIPANTS: VAERS
is the US national spontaneous
reporting system for adverse
events following vaccination.
Reports of GBS in persons 18
years or older following
influenza vaccination were
evaluated for each influenza
season from July 1, 1990,
through June 30, 2003. The
number of people vaccinated was
estimated from the National
Health Interview Survey and US
census data. Beginning in 1994,
active follow-up was conducted
to verify GBS diagnosis and
obtain other clinical details.
MAIN OUTCOME MEASURE: Reporting
rates of GBS following influenza
vaccination over time. RESULTS:
From July 1990 through June
2003, VAERS received 501 reports
of GBS following influenza
vaccination in adults. The
median onset interval (13 days)
was longer than that of non-GBS
reports of adverse events after
influenza vaccine (1 day)
(P<.001). The annual reporting
rate decreased 4-fold from a
high of 0.17 per 100,000
vaccinees in 1993-1994 to 0.04
in 2002-2003 (P<.001). A GBS
diagnosis was confirmed in 82%
of reports. Preceding illness
within 4 weeks of vaccination
was identified in 24% of
reported cases. CONCLUSIONS:
From 1990 to 2003, VAERS
reporting rates of GBS after
influenza vaccination decreased.
The long onset interval and low
prevalence of other preexisting
illnesses are consistent with a
possible causal association
between GBS and influenza
vaccine. These findings require
additional research, which can
lead to a fuller understanding
of the causes of GBS and its
possible relationship with
influenza vaccine.
=======================================================================
22.) Clinical implications of
endotoxin concentrations in
vaccines.
=======================================================================
Ann Pharmacother. 2002
May;36(5):776-80.
Geier DA, Geier MR.
Genetic Centers of America, 14
Redgate Court, Silver Spring, MD
20905-5726, USA.
Comment in:
· Ann Pharmacother. 2002
Oct;36(10):1650; author reply
1650-1.
BACKGROUND: A previous study
suggested that high
concentrations of endotoxin may
be present in whole-cell
diphtheria/tetanus/pertussis
(DTP) vaccine, and the
scientific literature contains
many studies examining the
reactivity of whole-cell DTP
vaccine. The medical and
scientific communities have
previously reported that the
presence of endotoxin in
commercial vaccines may have
negative effects on vaccine
recipients. OBJECTIVE: To
determine the endotoxin
concentrations in whole-cell
DTP, acellular DTP(DTaP), and DT
vaccines and determine the
clinical experience with each
vaccine. METHODS: To study the
endotoxin concentrations in
vaccines, the Limulus amebocyte
lysate (LAL) assay was used. The
vaccines analyzed with the LAL
assay were whole-cell DTP
vaccine lots manufactured by
Connaught, Lederle, the Michigan
and Massachusetts Departments of
Health, and Wyeth; DTaP vaccine
lots manufactured by Merieux and
Takeda; and DT vaccine lots
manufactured by Wyeth and
Lederle. The incidence of
adverse reactions following
whole-cell DTP, DTaP, and DT
vaccines were determined based
on analysis of the Vaccine
Adverse Events Reporting System
(VAERS) database. RESULTS: The
results of the LAL assay showed
that whole-cell DTP vaccines
contained considerably more
endotoxin than either DTaP or DT
vaccines. The VAERS showed that
statistically significantly more
adverse reactions were
associated with whole-cell DTP
vaccine than DTaP or DT
vaccines. CONCLUSIONS: This
analysis confirmed higher
concentrations of endotoxin in
whole-cell DTP vaccines compared
with DTaP or DT vaccines. As
high concentrations of endotoxin
may be correlated with a higher
incidence of adverse events, the
switch from whole-cell DTP to
DTaP for routine vaccinations in
the US seems well justified.
=======================================================================
23.) Guillain-Barré syndrome
after influenza vaccination in
adults: a population-based
study.
========================================================================
Arch Intern Med. 2006 Nov
13;166(20):2217-21.
Juurlink DN, Stukel TA, Kwong J,
Kopp A, McGeer A, Upshur RE,
Manuel DG, Moineddin R, Wilson
K.
Institute of Clinical Evaluative
Sciences, Sunnybrook and Women's
College Health Sciences Centre,
Toronto, Ontario.
BACKGROUND: Whether influenza
vaccination is associated with
Guillain-Barré syndrome (GBS)
remains uncertain. METHODS: We
conducted 2 studies using
population-based health care
data from the province of
Ontario, Canada. In the first
study, we used the self-matched
case-series method to explore
the temporal association between
probable influenza vaccination
(adults vaccinated during
October and November) and
subsequent hospitalization
because of GBS. In the second
study, we used time-series
analysis to determine whether
the institution of a universal
influenza immunization program
in October 2000 was associated
with a subsequent increase in
hospital admissions because of
GBS at the population level.
RESULTS: From April 1, 1992, to
March 31, 2004, we identified
1601 incident hospital
admissions because of GBS in
Ontario. In 269 patients, GBS
was diagnosed within 43 weeks of
vaccination against influenza.
The estimated relative incidence
of GBS during the primary risk
interval (weeks 2 through 7)
compared with the control
interval (weeks 20 through 43)
was 1.45 (95% confidence
interval, 1.05-1.99; P = .02).
This association persisted in
several sensitivity analyses
using risk and control intervals
of different durations. However,
a separate time-series analysis
demonstrated no evidence of
seasonality and revealed no
statistically significant
increase in hospital admissions
because of GBS after the
introduction of the universal
influenza immunization program.
CONCLUSION: Influenza
vaccination is associated with a
small but significantly
increased risk for
hospitalization because of GBS.
===================================================================
24.) Novel Pandemic Influenza
A(H1N1) Viruses Are Potently
Inhibited by DAS181, a Sialidase
Fusion Protein
=====================================================================
Gallen B. Triana-Baltzer,1
Larisa V. Gubareva,2 John M.
Nicholls,3 Melissa B. Pearce,2
Vasiliy P. Mishin,2 Jessica A.
Belser,2 Li-Mei Chen,2 Renee W.
Y. Chan,3 Michael C. W. Chan,3
Maria Hedlund,1 Jeffrey L.
Larson,1 Ronald B. Moss,1
Jacqueline M. Katz,2 Terrence M.
Tumpey,2 and Fang Fang1*
1NexBio, Inc., San Diego,
California, United States of
America
2Influenza Division, National
Center for Immunization and
Respiratory Diseases, Centers
for
Disease Control and Prevention,
Atlanta, Georgia, United States
of America
3Departments of Pathology and
Microbiology, University of Hong
Kong, Pok Fu Lam, Hong Kong
Special Administrative Region,
People's Republic of China
Cheryl A. Stoddart, Editor
University of California San
Francisco, United States of
America
* E-mail: [email protected]
Conceived and designed the
experiments: GBTB LG JMN VPM JAB
MH JLL RBm TMT FF. Performed the
experiments: LG JMN MBP VPM JAB
LMC RWYC MCC. Analyzed the data:
GBTB LG JMN VPM LMC RWYC MH RBm
JMK TMT FF. Contributed reagents/materials/analysis
tools: GBTB LG JMN VPM RWYC JMK
TMT FF. Wrote the paper: GBTB
JLL.
Received June 10, 2009; Accepted
October 13, 2009.
Abstract
Background
The recent emergence of a novel
pandemic influenza A(H1N1)
strain in humans exemplifies the
rapid and unpredictable nature
of influenza virus evolution and
the need for effective
therapeutics and vaccines to
control such outbreaks. However,
resistance to antivirals can be
a formidable problem as
evidenced by the currently
widespread oseltamivir- and
adamantane-resistant seasonal
influenza A viruses (IFV).
Additional antiviral approaches
with novel mechanisms of action
are needed to combat novel and
resistant influenza strains.
DAS181 (Fludase™) is a sialidase
fusion protein in early clinical
development with in vitro and in
vivo preclinical activity
against a variety of seasonal
influenza strains and highly
pathogenic avian influenza
strains (A/H5N1). Here, we use
in vitro, ex vivo, and in vivo
models to evaluate the activity
of DAS181 against several
pandemic influenza A(H1N1)
viruses.
Methods and Findings
The activity of DAS181 against
several pandemic influenza
A(H1N1) virus isolates was
examined in MDCK cells,
differentiated primary human
respiratory tract culture,
ex-vivo human bronchi tissue and
mice. DAS181 efficiently
inhibited viral replication in
each of these models and against
all tested pandemic influenza
A(H1N1) strains. DAS181
treatment also protected mice
from pandemic influenza A(H1N1)-induced
pathogenesis. Furthermore,
DAS181 antiviral activity
against pandemic influenza
A(H1N1) strains was comparable
to that observed against
seasonal influenza virus
including the H274Y oseltamivir-resistant
influenza virus.
Conclusions
The sialidase fusion protein
DAS181 exhibits potent
inhibitory activity against
pandemic influenza A(H1N1)
viruses. As inhibition was also
observed with oseltamivir-resistant
IFV (H274Y), DAS181 may be
active against the antigenically
novel pandemic influenza
A(H1N1) virus should it acquire
the H274Y mutation. Based on
these and previous results
demonstrating DAS181 broad-spectrum
anti-IFV activity, DAS181
represents a potential
therapeutic agent for prevention
and treatment of infections by
both emerging and seasonal
strains of IFV.
=======================================================================
25.)A one year followup of
chronic arthritis following
rubella and hepatitis B
vaccination based upon analysis
of the Vaccine Adverse Events
Reporting System (VAERS)
database.
========================================================================
Geier DA, Geier MR.
MedCon, Inc., Silver Spring,
Maryland, USA. [email protected]
OBJECTIVES: This analysis
examined the incidence rate of
chronic arthritis adverse
reactions reported following
adult rubella and hepatitis B
vaccinations. In this analysis,
etiologic mechanisms for chronic
arthritis following adult
rubella and hepatitis B vaccines
were also explored. METHODS: The
Vaccine Adverse Events Reporting
System (VAERS) database was
analyzed for the incidence rate
of reported cases of chronic
arthritis in comparison to
Tetanus-diphtheria (Td) and
tetanus toxoid adult vaccine
control groups. RESULTS: Chronic
arthritis adverse reactions
following adult rubella
vaccination were primarily
reported in females (female/male
ratio = 3.0), at about 45 years-old,
and at a mean onset time of
10-11 days following vaccination.
Chronic arthritis adverse
reactions following adult
hepatitis B vaccination were
also primarily reported in
females(female/male ratio =
3.5), at about 33 years-old, and
with a mean onset time of 16
days following vaccination. The
incidence rates of chronic
arthritis following adult
rubella and adult hepatitis B
vaccinations were statistically
significantly increased, by chi
2 analysis, in comparison to the
adult vaccine control groups.
The attributable risk of chronic
arthritis following adult
rubella vaccine ranged from 32
to 53 and from 5.1 to 9.0
following adult hepatitis B
vaccine in comparison to the
adult vaccine control groups.
CONCLUSION: This study revealed
that adult rubella and adult
hepatitis B vaccines were
statistically associated with
chronic arthritis which
persisted for at least one year.
The etiology for these adverse
reactions may involve autoimmune
mechanisms. Furthermore,
potential biases in the
reporting rates of adverse
reactions to VAERS were not
observed.
=======================================================================
26.) Investigation of the
temporal association of Guillain-Barre
syndrome with influenza vaccine
and influenzalike illness using
the United Kingdom General
Practice Research Database.
=======================================================================
Am J Epidemiol. 2009 Feb
1;169(3):382-8. Epub 2008 Nov 24
Stowe J, Andrews N, Wise L,
Miller E.
Immunisation Department, Health
Protection Agency Centre for
Infections, London, UK.
[email protected]
In 1976, the national swine
influenza vaccination program in
the United States was suspended
because of an increased risk of
Guillain-Barré syndrome.
Subsequent studies of seasonal
influenza vaccine have given
conflicting results. The authors
used the self-controlled case
series method to investigate the
relation of Guillain-Barré
syndrome with influenza vaccine
and influenzalike illness using
cases recorded in the General
Practice Research Database from
1990 to 2005 in the United
Kingdom. The relative incidence
of Guillain-Barré syndrome
within 90 days of vaccination
was 0.76 (95% confidence
interval: 0.41, 1.40). In
contrast, the relative incidence
of Guillain-Barré syndrome
within 90 days of an
influenzalike illness was 7.35
(95% confidence interval: 4.36,
12.38), with the greatest
relative incidence (16.64, 95%
confidence interval: 9.37,
29.54) within 30 days. The
relative incidence was similar
(0.89, 95% confidence interval:
0.42, 1.89) when the analysis
was restricted to a subset of
validated cases. The authors
found no evidence of an
increased risk of Guillain-Barré
syndrome after seasonal
influenza vaccine. The finding
of a greatly increased risk
after influenzalike illness is
consistent with anecdotal
reports of a preceding
respiratory illness in Guillain-Barré
syndrome and has important
implications for the risk/benefit
assessment that would be carried
out should pandemic vaccines be
deployed in the future.
=======================================================================
27.) Update: Guillain-Barré
syndrome among recipients of
Menactra meningococcal conjugate
vaccine--United States, June
2005-September 2006.
=======================================================================
MMWR Morb Mortal Wkly Rep. 2006
Oct 20;55(41):1120-4.
Centers for Disease Control and
Prevention (CDC).
Erratum in:
· MMWR Morb Mortal Wkly
Rep. 2006 Nov 3;55(43):1177.
In October 2005, reports
indicating a possible
association between Guillain-Barré
Syndrome (GBS) and receipt of
meningococcal conjugate vaccine
(MCV4) (Menactra, Sanofi
Pasteur, Inc., Swiftwater,
Pennsylvania) were made to the
Vaccine Adverse Event Reporting
System (VAERS). GBS is a serious
neurologic disorder involving
inflammatory demyelination of
the peripheral nerves. During
March 2005-February 2006, eight
confirmed cases had occurred
within 6 weeks (i.e., the time
window of elevated risk noted
for GBS after administration of
other vaccines) after MCV4
vaccination. This report
summarizes nine additional GBS
cases reported to VAERS during
March-September 2006. This
report also provides a
preliminary analysis of data
from VAERS and the Vaccine
Safety Datalink (VSD) since MCV4
became available in the United
States in March 2005 and
includes all 17 cases of GBS
reported since June 2005.
Although these data suggest a
small increased risk for GBS
after MCV4 vaccination, the
inherent limitations of VAERS
and the uncertainty regarding
background incidence rates for
GBS require that these findings
be viewed with caution. Because
of the risk for meningococcal
disease and the associated
morbidity and mortality, CDC
continues to recommend routine
vaccination with MCV4 for
adolescents, college freshmen
living in dormitories, and other
populations at increased risk.
=======================================================================
28.) Guillain-Barre syndrome
following vaccination in the
National Influenza Immunization
Program, United States,
1976--1977.
=======================================================================
Am J Epidemiol. 1979 Aug;110(2):105-23
Schonberger LB, Bregman DJ,
Sullivan-Bolyai JZ, Keenlyside
RA, Ziegler DW, Retailliau HF,
Eddins DL, Bryan JA.
Because of an increase in the
number of reports of Guillian-Barre
syndrome (GBS) following A/New
Jersey influenza vaccination,
the National Influenza
Immunization Program was
suspended December 16, 1976 and
nationwide surveillance for GBS
was begun. This surveillance
uncovered a total of 1098
patients with onset of GBS from
October 1, 1976, to January 31,
1977, from all 50 states,
District of Columbia, and Puerto
Rico. A total of 532 patients
had recently received an A/New
Jersey influenza vaccination
prior to their onset of GBS (vaccinated
cases), and 15 patients received
a vaccination after their onset
of GBS. Five hundred forty-three
patients had not been recently
vaccinated with A/New Jersey
influenza vaccine and the
vaccination status for 8 was
unknown. Epidemiologic evidence
indicated that many cases of GBS
were related to vaccination.
When compared to the
unvaccinated population, the
vaccinated population had a
significantly elevated attack
rate in every adult age group.
The estimated attributable risk
of vaccine-related GBS in the
adult population was just under
one case per 100,000
vaccinations. The period of
increased risk was concentrated
primarily within the 5-week
period after vaccination,
although it lasted for
approximately 9 or 10 weeks.
====================================================================
29.) Adverse events after
inactivated influenza
vaccination among children less
than 2 years of age: analysis of
reports from the vaccine adverse
event reporting system,
1990-2003.
=====================================================================
Pediatrics. 2005 Feb;115(2):453-60.
McMahon AW, Iskander J, Haber P,
Chang S, Woo EJ, Braun MM, Ball
R.
Division of Epidemiology, Office
of Biostatistics and
Epidemiology, Center for
Biologics Evaluation and
Research, Food and Drug
Administration, 1401 Rockville
Pike, Rockville,
Maryland 20852, USA. [email protected]
BACKGROUND: In April 2002, the
Advisory Committee on
Immunization Practices (ACIP)
encouraged providers to
vaccinate healthy 6- to 23-month-old
infants and children with
trivalent influenza vaccine
(TIV). OBJECTIVES: To describe
adverse events (AEs) reported to
the Vaccine Adverse Event
Reporting System (VAERS) after
TIV vaccination among children
<2 years of age and to compare
reports before the ACIP
guideline (January 1990 to June
2002) and after the ACIP
guideline (July 2002 to June
2003). METHODS: VAERS is a
passive vaccine safety
surveillance system begun by the
Food and Drug Administration and
the Centers for Disease Control
and Prevention in 1990. We
reviewed reports to VAERS for
children <2 years of age who
received TIV, alone or in
combination with other vaccines.
Influenza seasons were defined
as the period from July 1 of one
year to June 30 of the following
year. RESULTS: Between 1990 and
2003, VAERS received 166 TIV
reports for children <2 years of
age. There were 62 reports (37%)
after administration of TIV
alone and 104 reports (63%)
after administration of TIV and
> or =1 other vaccine.
Approximately one third of
reports (N = 61) were in the
post-ACIP guideline period. The
4 most frequent AE coding terms
were fever (N = 59, 35%),
unspecified or urticarial rash
(42, 25%), seizure (28, 17%),
and injection site reaction (28,
17%). The median number of days
from vaccination to symptom
onset, the percentage of reports
that represented serious AEs,
and the gender distribution were
similar in the pre-ACIP
guideline and post-ACIP
guideline periods. The
percentage of reports describing
an underlying medical condition
for the subject decreased from
58% before the ACIP guideline to
37% after the ACIP guideline.
Nineteen of 28 seizure reports
(68%) described fever with the
seizure within 2 days after
vaccination. Seizure was the
most frequent coding term (N =
10, 7 with fever) among 23
serious reports. The annual
number of TIV-related VAERS
reports for children <2 years of
age increased in the post-ACIP
guideline period, probably at
least in part because of an
increase in the number of
vaccinees after the ACIP
announcement. The safety
profiles in the pre-ACIP
guideline and post-ACIP
guideline periods were similar.
CONCLUSIONS: In October 2003,
the ACIP recommended that all
healthy children 6 to 23 months
of age be vaccinated with TIV,
starting in the 2004-2005
influenza season. This study
provides generally reassuring,
although limited, data regarding
the safety of TIV among children
in this age range. Continued
surveillance for seizures and
other clinically significant AEs
is warranted and will continue.
================================================================
30.)Vaccines and Guillain-Barré
syndrome.
===============================================================
Haber P, Sejvar J, Mikaeloff Y,
DeStefano F.
Drug Saf. 2009;32(4):309-23. doi:
10.2165/00002018-200932040-00005.
Immunization Safety Office,
Office of the Chief Science
Officer, Centers for Disease
Control and Prevention, Atlanta,
Georgia 30333, USA. [email protected]
Guillain-Barré syndrome (GBS) is
the leading cause of acute
flaccid paralysis in developed
countries and is characterized
by various degrees of weakness,
sensory abnormalities and
autonomic dysfunction. Although
the underlying aetiology and
pathophysiology of GBS are not
completely understood, it is
broadly believed that immune
stimulation plays a role in its
pathogenesis. Thus, since
vaccines have an effect on the
immune system it is biologically
plausible that immunizations may
be associated with subsequent
GBS. The objective of this
article is to review the current
body of evidence that either
supports or does not support a
causal, rather than just
temporal, association between
various vaccines and GBS, and to
provide an evidence-based review
of this issue. The scope of the
article includes published
reports that, regardless of
method of case ascertainment,
appeared in peer-reviewed
literature between 1950 and
2008. Our review indicates that,
with rare exceptions,
associations between vaccines
and GBS have been only temporal.
There is little evidence to
support a causal association
with most vaccines. The evidence
for a causal association is
strongest for the swine
influenza vaccine that was used
in 1976-77. Studies of influenza
vaccines used in subsequent
years, however, have found small
or no increased risk of GBS.
Older formulations of rabies
vaccine cultured in mammalian
brain tissues have been found to
have an increased risk of GBS,
but newer formulations of rabies
vaccine, derived from chick
embryo cells, do not appear to
be associated with GBS at a
greater than expected rate. In
an earlier review, the Institute
of Medicine concluded that the
evidence favoured a causal
association between oral polio
vaccine and tetanus toxoid-containing
vaccines and GBS. However,
recent evidence from large
epidemiological studies and mass
immunization campaigns in
different countries found no
correlation between oral polio
vaccine or tetanus toxoid-containing
vaccines and GBS. Spontaneous
reports to the US Vaccine
Adverse Events Reporting System
shortly after the introduction
of quadrivalent conjugated
meningococcal vaccine (MCV4)
raised concerns of a possible
association with GBS.
Comparisons with expected rates
of GBS, however, were
inconclusive for an increased
risk, and lack of controlled
epidemiological studies makes it
difficult to draw conclusions
about a causal association. For
other vaccines, available data
are based on isolated case
reports or very small clusters
temporally related to
immunizations, and no conclusion
about causality can be drawn.
There are certain circumstances
in which immunizing individuals,
particularly those with a prior
history of GBS, may require
caution. However, the benefit of
vaccines in preventing disease
and decreasing morbidity and
mortality, particularly for
influenza, needs to be weighed
against the potential risk of
GBS.
======================================================================
31.) potential signal of
Bell's palsy after parenteral
inactivated influenza vaccines:
reports to the Vaccine Adverse
Event Reporting System (VAERS)--United
States, 1991-2001.
=========================================================================
Pharmacoepidemiol Drug Saf. 2004
Aug;13(8):505-10.
Zhou W, Pool V, DeStefano F,
Iskander JK, Haber P, Chen RT;
VAERS Working Group.
Epidemic Intelligence Service,
Epidemiology Program Office,
Centers for Disease Control and
Prevention, Atlanta, GA 30333,
USA.
Comment in:
· Pharmacoepidemiol Drug Saf.
2004 Aug;13(8):501-2.
· Pharmacoepidemiol Drug Saf.
2004 Aug;13(8):511-3; discussion
515-7.
PURPOSE: Post-licensure
experience with a new intranasal
inactivated influenza vaccine in
Switzerland recently identified
an increased risk for Bell's
palsy. We reviewed reports in
the Vaccine Adverse Event
Reporting System (VAERS) to
assess if parenteral inactivated
influenza vaccines (influenza
vaccines) may also increase the
risk for Bell's palsy. METHODS:
Reports of Bell's palsy after
influenza vaccines in VAERS from
1/1/1991 to 12/31/2001 were
identified by searching the
Coding Symbols for Thesaurus of
Adverse Reaction Terms (COSTART)
for 'paralysis facial' and by
text string search in the
automated database. The text
descriptions on each report were
reviewed to verify the
diagnosis. The proportional
reporting ratio (PRR) was
calculated to aid signal
detection. RESULTS: We found a
total of 197 reports of Bell's
palsy after receipt of influenza
vaccines. The diagnosis was
verified for 154 (78.2%), of
which 145 (94.2%) had received
influenza vaccines alone. The
verified reports were submitted
from 35 states; 58% of the
reports involved persons living
in states where the risk of Lyme
disease, which can also cause
facial paralysis, was low,
minimal or none. The PRRs in all
age groups exceeded the criteria
for a signal of possible
association. The highest PRR was
3.91 in the > or = 65 years age
group. CONCLUSIONS: Our findings
revealed a signal of possible
association between influenza
vaccines and an increased risk
of Bell's palsy. A
population-based controlled
study is needed to determine
whether this association could
be causal and to quantify the
risk. 2004 by John Wiley & Sons,
Ltd.
========================================================================
32.) Adverse events reported
following live, cold-adapted,
intranasal influenza vaccine.
========================================================================
JAMA. 2005 Dec 7;294(21):2720-5.
Izurieta HS, Haber P, Wise RP,
Iskander J, Pratt D, Mink C,
Chang S, Braun MM, Ball R.
Center for Biologics Evaluation
and Research, Food and Drug
Administration, Rockville, Md
20852-1448, USA. [email protected]
Erratum in:
· JAMA. 2005 Dec
28;294(24):3092.
Comment in:
· JAMA. 2005 Dec
7;294(21):2763-5.
CONTEXT: In June 2003, the US
Food and Drug Administration
licensed a trivalent live,
attenuated influenza vaccine (LAIV-T)
for intranasal administration to
healthy persons 5 to 49 years of
age. Although prelicensure
testing involved 20 228
vaccinees, clinical trials were
not of sufficient size to detect
rare adverse events reliably.
OBJECTIVE: To identify adverse
events reported following LAIV-T
administration after licensure.
DESIGN, SETTING, AND
PARTICIPANTS: All adverse events
reported to the US Vaccine
Adverse Event Reporting System (VAERS)
during the 2003-2004 and the
2004-2005 influenza seasons.
MAIN OUTCOME MEASURES: Numbers
and proportions of reported
adverse events and reporting
rates of adverse events per
100,000 vaccinees. RESULTS:
Approximately 2,500,000 persons
received LAIV-T during the first
2 postlicensure seasons. As of
August 16, 2005, VAERS received
460 adverse event reports for
vaccinations received from
August 2003 through July 2005.
No fatalities were reported.
There were 7 reports of possible
anaphylaxis, 2 reports of
Guillain-Barré syndrome, 1
report of Bell palsy, and 8
reports of asthma exacerbation
among individuals with a prior
asthma history. Events in
individuals for whom the vaccine
was not indicated accounted for
73 reports (16%). CONCLUSIONS:
Reports to VAERS in the first 2
seasons of LAIV-T use did not
identify any unexpected serious
risks with this vaccine when
used according to approved
indications. Like many vaccines
and other medical products, LAIV-T
may rarely cause anaphylaxis.
Secondary transmission of the
vaccine virus merits further
investigation. Reports of asthma
exacerbations in vaccinees with
prior asthma history highlight
the risks of vaccine use
inconsistent with approved
labeling.
======================================================================
33.) Monitoring the safety of
annual and pandemic influenza
vaccines: lessons from the US
experience.
======================================================================
Expert Rev Vaccines. 2008
Feb;7(1):75-82.
Iskander J, Broder K.
US Public Health Service,
Immunization Safety Office,
Office of Chief Science Officer,
Centers for Disease Control and
Prevention, 1600 Clifton Road,
MS D-26, Atlanta, GA 30333, USA.
[email protected]
Annual use of influenza vaccines
represents the largest vaccine
campaign conducted in the USA.
Recent expansions in influenza
vaccine recommendations suggest
a move toward 'universal'
vaccination strategies. Although
a great deal of safety data has
been accumulated, concerns
remain regarding rare, serious
adverse events following
immunization. A proven
association between the
1976-1977 swine influenza
vaccine and Guillain-Barré
syndrome halted that particular
national vaccination campaign.
Recently, annual influenza
vaccines have been associated
with novel adverse events, for
example, oculorespiratory
syndrome in Canada. Any vaccine
used against an influenza strain
of pandemic potential will have
an incompletely described safety
profile. Thus, the challenge of
influenza vaccine safety is to
detect new safety concerns that
may arise during seasonal
campaigns, while preparing
vaccine safety systems for the
timely detection of adverse
events in the setting of a
pandemic.
===========================================================
34.) Are toxic biometals
destroying your children's
future?
===========================================================
Biometals. 2009
Oct;22(5):697-700. Epub 2009 Feb
11
Drum DA.
[email protected]
Cadmium, arsenic, lead, and
mercury have been linked to
autism, attention deficit
disorder, mental retardation and
death of children. Mercury in
thimerosal found in many
vaccines and flu shots
contributes significantly to
these problems. Decomposition of
the thimerosal can produce more
toxic compounds, either
methylethylmercury or
diethylmercury, in the body.
These compounds have a toxicity
level similar to dimethylmercury.
Within the human body, a
mitochondrial disorder may
release the more toxic form of
mercury internally. Young
children and pregnant women must
minimize internal exposure to
the vaccines and flu shots
containing mercury.
=====================================================================
35.) Surveillance for safety
after immunization: Vaccine
Adverse Event Reporting System
(VAERS)--United States,
1991-2001.
======================================================================
MMWR Surveill Summ. 2003 Jan
24;52(1):1-24
Zhou W, Pool V, Iskander JK,
English-Bullard R, Ball R, Wise
RP, Haber P, Pless RP, Mootrey
G, Ellenberg SS, Braun MM, Chen
RT.
Epidemic Intelligence Service
Program, Epidemiology Program
Office, CDC, USA.
Erratum in:
· MMWR Morb Mortal Wkly Rep.
2003 Feb 14;52(06):113.
PROBLEM/CONDITION: Vaccines are
usually administered to healthy
persons who have substantial
expectations for the safety of
the vaccines. Adverse events
after vaccinations occur but are
generally rare. Some adverse
events are unlikely to be
detected in prelicensure
clinical trials because of their
low frequency, the limited
numbers of enrolled subjects,
and other study limitations.
Therefore, postmarketing
monitoring of adverse events
after vaccinations is essential.
The cornerstone of monitoring
safety is review and analysis of
spontaneously reported adverse
events. REPORTING PERIOD
COVERED: This report summarizes
the adverse events reported to
the Vaccine Adverse Event
Reporting System (VAERS) from
January 1, 1991, through
December 31, 2001. DESCRIPTION
OF SYSTEMS: VAERS was
established in 1990 under the
joint administration of CDC and
the Food and Drug Administration
(FDA) to accept reports of
suspected adverse events after
administration of any vaccine
licensed in the United States.
VAERS is a passive surveillance
system: reports of events are
voluntarily submitted by those
who experience them, their
caregivers, or others. Passive
surveillance systems (e.g.,
VAERS) are subject to multiple
limitations, including
underreporting, reporting of
temporal associations or
unconfirmed diagnoses, and lack
of denominator data and unbiased
comparison groups. Because of
these limitations, determining
causal associations between
vaccines and adverse events from
VAERS reports is usually not
possible. Vaccine safety
concerns identified through
adverse event monitoring nearly
always require confirmation
using an epidemiologic or other
(e.g., laboratory) study.
Reports may be submitted by
anyone suspecting that an
adverse event might have been
caused by vaccination and are
usually submitted by mail or
fax. A web-based electronic
reporting system has recently
become available. Information
from the reports is entered into
the VAERS database, and new
reports are analyzed weekly.
VAERS data stripped of personal
identifiers can be reviewed by
the public by accessing http://www.vaers.org.
The objectives of VAERS are to
1) detect new, unusual, or rare
vaccine adverse events; 2)
monitor increases in known
adverse events; 3) determine
patient risk factors for
particular types of adverse
events; 4) identify vaccine lots
with increased numbers or types
of reported adverse events; and
5) assess the safety of newly
licensed vaccines. RESULTS:
During 1991-2001, VAERS received
128,717 reports, whereas >1.9
billion net doses of human
vaccines were distributed. The
overall dose-based reporting
rate for the 27 frequently
reported vaccine types was 11.4
reports per 100,000 net doses
distributed. The proportions of
reports in the age groups <1
year, 1-6 years, 7-17 years,
18-64 years, and >/= years were
18.1%, 26.7%, 8.0%, 32.6%, and
4.9%, respectively. In all of
the adult age groups, a
predominance among the number of
women reporting was observed,
but the difference in sex was
minimal among children. Overall,
the most commonly reported
adverse event was fever, which
appeared in 25.8% of all
reports, followed by
injection-site hypersensitivity
(15.8%), rash (unspecified)
(11.0%), injection-site edema
(10.8%), and vasodilatation
(10.8%). A total of 14.2% of all
reports described serious
adverse events, which by
regulatory definition include
death, life-threatening illness,
hospitalization or prolongation
of hospitalization, or permanent
disability. Examples of the uses
of VAERS data for vaccine safety
surveillance are included in
this report. INTERPRETATION: As
a national public health
surveillance system, VAERS is a
key component in ensuring the
safety of vaccines. VAERS data
are used by CDC, FDA, and other
organizations to monitor and
study vaccine safety. CDC and
FDA use VAERS data to respond to
public inquiries regarding
vaccine safety, and both
organizations have published and
presented vaccine safety studies
based on VAERS data. VAERS data
are also used by the Advisory
Committee on Immunization
Practices and the Vaccine and
Related Biological Products
Advisory Committee to evaluate
possible adverse events after
vaccinations and to develop
recommendations for precautions
and contraindications to
vaccinations. Reviews of VAERS
reports and the studies based on
VAERS reports during 1991-2001
have demonstrated that vaccines
are usually safe and that
serious adverse events occur but
are rare. PUBLIC HEALTH ACTIONS:
Through continued reporting of
adverse events after vaccination
to VAERS by health-care
providers, public health
professionals, and the public
and monitoring of reported
events by the VAERS working
group, the public health system
will continue to be able to
detect rare but potentially
serious consequences of
vaccination. This knowledge
facilitates improvement in the
safety of vaccines and the
vaccination process.
====================================================================
36.) Media coverage of the
measles-mumps-rubella vaccine
and autism controversy and its
relationship to MMR immunization
rates in the United States.
====================================================================
Pediatrics. 2008
Apr;121(4):e836-43.
Smith MJ, Ellenberg SS, Bell LM,
Rubin DM.
Division of Infectious Diseases,
Children's Hospital of
Philadelphia, Philadelphia,
Pennsylvania, USA. [email protected]
Comment in:
· Pediatrics. 2008
Sep;122(3):684-5; author reply
685-6.
OBJECTIVE: The purpose of this
work was to assess the
association between media
coverage of the MMR-autism
controversy and MMR immunization
in the United States. METHODS:
The public-use files of the
National Immunization Survey
were used to estimate annual MMR
coverage from 1995 to 2004. The
primary outcome was selective
measles-mumps-rubella nonreceipt,
that is, those children who
received all childhood
immunizations except MMR. Media
coverage was measured by using
LexisNexis, a comprehensive
database of national and local
news media. Factors associated
with MMR nonreceipt were
identified by using a logistic
regression model. RESULTS:
Selective MMR nonreceipt,
occurring in as few as 0.77% of
children in the 1995 cohort,
rose to 2.1% in the 2000
National Immunization Survey.
Children included in the 2000
National Immunization Survey
were born when the putative link
between MMR and autism surfaced
in the medical literature but
before any significant media
attention occurred. Selective
nonreceipt was more prevalent in
private practices and unrelated
to family characteristics. MMR
nonreceipt returned to baseline
before sustained media coverage
of the MMR-autism story began.
CONCLUSIONS: There was a
significant increase in
selective MMR nonreceipt that
was temporally associated with
the publication of the original
scientific literature,
suggesting a link between MMR
and autism, which preceded media
coverage of the MMR-autism
controversy. This finding
suggests a limited influence of
mainstream media on MMR
immunization in the United
States.
========================================================================
37.) A meta-analysis
epidemiological assessment of
neurodevelopmental disorders
following vaccines administered
from 1994 through 2000 in the
United States.
=======================================================================
Neuro Endocrinol Lett. 2006
Aug;27(4):401-13.
Geier DA, Geier MR.
The Institute for Chronic
Illnesses, Inc., Silver Spring,
MD 20905, USA. [email protected]
BACKGROUND: Thimerosal is an
ethylmercury-containing compound
(49.6% mercury by weight) used
as at the preservative level in
vaccines (0.005% to 0.01%).
METHODS: Statistical modeling in
a meta-analysis epidemiological
assessment of the Vaccine
Adverse Event Reporting System (VAERS)
for neurodevelopment disorders (NDs)
reported following
Diphtheria-Tetanus-whole-cell-Pertussis
(DTP) vaccines in comparison to
Diphtheria-Tetanus-whole-cell-Pertussis-Haemophilus
Influenzae Type b (DTPH)
vaccines (administered:
1994-1997) and following
Thimerosal-containing
Diphtheria-Tetanus-acellular-Pertussis
(DTaP), vaccines in comparison
to Thimerosal-free DTaP vaccines
(administered: 1997-2000), was
undertaken. RESULTS:
Significantly increased adjusted
(sex, age, vaccine type, vaccine
manufacturer) risks of autism,
speech disorders, mental
retardation, personality
disorders, thinking
abnormalities, ataxia, and NDs
in general, with minimal
systematic error or confounding,
were associated with TCV
exposure. CONCLUSION: It is
clear from the results of the
present epidemiological study
and other recently published
data associating mercury
exposure with childhood NDs,
additional ND research should be
undertaken in the context of
evaluating mercury-associated
exposures, especially from
Thimerosal-containing vaccines.
====================================================================
38.) An evaluation of the
effects of thimerosal on
neurodevelopmental disorders
reported following DTP and Hib
vaccines in comparison to DTPH
vaccine in the United States.
====================================================================
J Toxicol Environ Health A. 2006
Aug;69(15):1481-95.
Geier DA, Geier MR.
The Genetic Centers of America,
Silver Spring, Maryland 20905,
USA. [email protected]
Thimerosal is an ethylmercury
(49.55% mercury by weight)
preservative historically added
to some vaccines. Toxicokinetic
studies showed children in the
United States received doses of
mercury from Thimerosal-containing
vaccines (TCVs) in excess of
safety guidelines. In the United
States during the 1990s,
diphtheria-tetanus-pertussis
(DTP) and Haemophilus influenzae
type b (Hib) vaccines
(maximally, 50 mug mercury per
joint administration) and
diphtheria-tetanus-pertussis-Haemophilus
influenzae type b (DTPH)
vaccines (25 mug mercury per
administration) were given to
children in the same childhood
vaccination schedule at 2, 4, 6,
and 15-18 mo, so that children
receiving DTP and Hib vaccines
may have maximally received an
additional 100 mug more mercury
exposure from TCVs than children
administered DTPH vaccines. A
case-control epidemiological
study of neurodevelopmental
disorders (NDs) reported to the
Vaccine Adverse Event Reporting
System (VAERS) (online public
access version; updated 31
August 2004) following
administration of DTP vaccines
in comparison DTPH vaccines
manufactured by Lederle
Laboratories (Pearl River, NY)
from 1994 through 1998 was
undertaken. Significantly
increased odds ratios for
autism, speech disorders, mental
retardation, infantile spasms,
and thinking abnormalities
reported to VAERS were found
following DTP vaccines in
comparison to DTPH vaccines with
minimal bias or systematic
error. Additional ND research
should be undertaken in the
context of evaluating
mercury-associated exposures,
especially since in 2005 the
Institute of Medicine issued a
report calling into question
handling of vaccine safety data
by the National Immunization
Program of the Centers for
Disease Control and Prevention
=======================================================================
39.) Neurodevelopmental
disorders following thimerosal-containing
childhood immunizations: a
follow-up analysis.
=======================================================================
Int J Toxicol. 2004
Nov-Dec;23(6):369-76.
Geier D, Geier MR.
MedCon, Inc., Maryland, USA.
The authors previously published
the first epidemiological study
from the United States
associating thimerosal from
childhood vaccines with
neurodevelopmental disorders (NDs)
based upon assessment of the
Vaccine Adverse Event Reporting
System (VAERS). A number of
years have gone by since their
previous analysis of the VAERS.
The present study was undertaken
to determine whether the
previously observed effect
between thimerosal-containing
childhood vaccines and NDs are
still apparent in the VAERS as
children have had a chance to
further mature and potentially
be diagnosed with additional NDs.
In the present study, a cohort
of children receiving thimerosal-containing
diphtheria-tetanus-acellular
pertussis (DTaP) vaccines in
comparison to a cohort of
children receiving thimerosal-free
DTaP vaccines administered from
1997 through 2000 based upon an
assessment of adverse events
reported to the VAERS were
evaluated. It was determined
that there were significantly
increased odds ratios (ORs) for
autism (OR = 1.8, p < .05),
mental retardation (OR = 2.6, p
< .002), speech disorder (OR =
2.1, p < .02), personality
disorders (OR = 2.6, p < .01),
and thinking abnormality (OR =
8.2, p < .01) adverse events
reported to the VAERS following
thimerosal-containing DTaP
vaccines in comparison to
thimerosal-free DTaP vaccines.
Potential confounders and
reporting biases were found to
be minimal in this assessment of
the VAERS. It was observed, even
though the media has reported a
potential association between
autism and thimerosal exposure,
that the other NDs analyzed in
this assessment of the VAERS had
significantly higher ORs than
autism following thimerosal-containing
DTaP vaccines in comparison to
thimerosal-free DTaP vaccines.
The present study provides
additional epidemiological
evidence supporting previous
epidemiological, clinical and
experimental evidence that
administration of thimerosal-containing
vaccines in the United States
resulted in a significant number
of children developing NDs.
================================================================
40.) Neurodevelopmental
disorders after thimerosal-containing
vaccines: a brief communication.
=================================================================
Exp Biol Med (Maywood). 2003
Jun;228(6):660-4.
Geier MR, Geier DA.
The Genetic Centers of America,
Silver Spring, Maryland 20905,
USA. [email protected]
Comment in:
· Exp Biol Med (Maywood). 2003
Oct;228(9):991-2; discussion
993-4.
We were initially highly
skeptical that differences in
the concentrations of thimerosal
in vaccines would have any
effect on the incidence rate of
neurodevelopmental disorders
after childhood immunization.
This study presents the first
epidemiologic evidence, based
upon tens of millions of doses
of vaccine administered in the
United States, that associates
increasing thimerosal from
vaccines with neurodevelopmental
disorders. Specifically, an
analysis of the Vaccine Adverse
Events Reporting System (VAERS)
database showed statistical
increases in the incidence rate
of autism (relative risk [RR] =
6.0), mental retardation (RR =
6.1), and speech disorders (RR =
2.2) after thimerosal-containing
diphtheria, tetanus, and
acellular pertussis (DTaP)
vaccines in comparison with
thimerosal-free DTaP vaccines.
The male/female ratio indicated
that autism (17) and speech
disorders (2.3) were reported
more in males than females after
thimerosal-containing DTaP
vaccines, whereas mental
retardation (1.2) was more
evenly reported among male and
female vaccine recipients.
Controls were employed to
determine if biases were present
in the data, but none were
found. It was determined that
overall adverse reactions were
reported in similar-aged
populations after thimerosal-containing
DTaP (2.4 +/- 3.2 years old) and
thimerosal-free DTaP (2.1 +/-
2.8 years old) vaccinations.
Acute control adverse reactions
such as deaths (RR = 1.0),
vasculitis (RR = 1.2), seizures
(RR = 1.6), ED visits (RR =
1.4), total adverse reactions
(RR = 1.4), and gastroenteritis
(RR = 1.1) were reported
similarly after thimerosal-containing
and thimerosal-free DTaP
vaccines. An association between
neurodevelopmental disorders and
thimerosal-containing DTaP
vaccines was found, but
additional studies should be
conducted to confirm and extend
this study.
========================================================================
41.) A comparative evaluation
of the effects of MMR
immunization and mercury doses
from thimerosal-containing
childhood vaccines on the
population prevalence of autism.
========================================================================
Med Sci Monit. 2004
Mar;10(3):PI33-9. Epub 2004 Mar
1.
Geier DA, Geier MR.=
President, MedCon, Inc, Silver
Spring, MD, USA.
Comment in:
· Med Sci Monit. 2005
Oct;11(10):LE13-4.
BACKGROUND: The purpose of the
study was to evaluate the
effects of MMR immunization and
mercury from
thimerosal-containing childhood
vaccines on the prevalence of
autism. MATERIAL/METHODS:
Evaluations of the Biological
Surveillance Summaries of the
Centers for Disease Control and
Prevention (CDC), the U.S.
Department of Education
datasets, and the CDC's yearly
live birth estimates were
undertaken RESULTS: It was
determined that there was a
close correlation between
mercury doses from
thimerosal--containing childhood
vaccines and the prevalence of
autism from the late 1980s
through the mid-1990s. In
contrast, there was a potential
correlation between the number
of primary pediatric
measles-containing vaccines
administered and the prevalence
of autism during the 1980s. In
addition, it was found that
there were statistically
significant odds ratios for the
development of autism following
increasing doses of mercury from
thimerosal-containing vaccines
(birth cohorts: 1985 and
1990-1995) in comparison to a
baseline measurement (birth
cohort: 1984). The contribution
of thimerosal from childhood
vaccines (>50% effect) was
greater than MMR vaccine on the
prevalence of autism observed in
this study. CONCLUSIONS: The
results of this study agree with
a number of previously published
studies. These studies have
shown that there is biological
plausibility and epidemiological
evidence showing a direct
relationship between increasing
doses of mercury from
thimerosal-containing vaccines
and neurodevelopmental
disorders, and
measles-containing vaccines and
serious neurological disorders.
It is recommended that
thimerosal be removed from all
vaccines, and additional
research be undertaken to
produce a MMR vaccine with an
improved safety profile
=======================================================================
42.) Aluminum adjuvant linked
to Gulf War illness induces
motor neuron death in mice.
======================================================================
Neuromolecular Med.
2007;9(1):83-100.
Petrik MS, Wong MC, Tabata RC,
Garry RF, Shaw CA.
Department of Ophthalmology and
Program in Neuroscience,
University of British Columbia,
Vancouver, British Columbia,
Canada.
[email protected]
Gulf War illness (GWI) affects a
significant percentage of
veterans of the 1991 conflict,
but its origin remains unknown.
Associated with some cases of
GWI are increased incidences of
amyotrophic lateral sclerosis
and other neurological
disorders. Whereas many
environmental factors have been
linked to GWI, the role of the
anthrax vaccine has come under
increasing scrutiny. Among the
vaccine's potentially toxic
components are the adjuvants
aluminum hydroxide and squalene.
To examine whether these
compounds might contribute to
neuronal deficits associated
with GWI, an animal model for
examining the potential
neurological impact of aluminum
hydroxide, squalene, or aluminum
hydroxide combined with squalene
was developed. Young, male
colony CD-1 mice were injected
with the adjuvants at doses
equivalent to those given to US
military service personnel. All
mice were subjected to a battery
of motor and
cognitive-behavioral tests over
a 6-mo period postinjections.
Following sacrifice, central
nervous system tissues were
examined using
immunohistochemistry for
evidence of inflammation and
cell death. Behavioral testing
showed motor deficits in the
aluminum treatment group that
expressed as a progressive
decrease in strength measured by
the wire-mesh hang test (final
deficit at 24 wk; about 50%).
Significant cognitive deficits
in water-maze learning were
observed in the combined
aluminum and squalene group (4.3
errors per trial) compared with
the controls (0.2 errors per
trial) after 20 wk. Apoptotic
neurons were identified in
aluminum-injected animals that
showed significantly increased
activated caspase-3 labeling in
lumbar spinal cord (255%) and
primary motor cortex (192%)
compared with the controls.
Aluminum-treated groups also
showed significant motor neuron
loss (35%) and increased numbers
of astrocytes (350%) in the
lumbar spinal cord. The findings
suggest a possible role for the
aluminum adjuvant in some
neurological features associated
with GWI and possibly an
additional role for the
combination of adjuvants
====================================================================
43.) Influenza vaccine with
squalene adjuvant: new
preparation. No better than
available products.
=====================================================================
Prescrire Int. 2004
Dec;13(74):206-8.
[No authors listed]
(1) Injectable influenza
vaccines reduce morbidity and
mortality in people over 65
years. (2) A new influenza
vaccine, with an adjuvant
(MF59C.1) based on squalene, is
now marketed in France for
people over 65, and especially
those with chronic conditions at
risk of influenza complications.
(3) The clinical evaluation
dossier contains data from about
twenty immunogenicity studies in
more than 4000 elderly subjects.
According to a meta-analysis of
these studies, there is no firm
evidence that the MF59C.1
adjuvant vaccine is any better
than other vaccines at inducing
immunity in elderly people with
chronic conditions. (4) A
retrospective analysis of
mortality among subjects
enrolled in immunogenicity
studies showed no significant
difference between groups
receiving the squalene adjuvant
vaccine and groups receiving
another influenza vaccine,
either in the general population
or in subsets of patients with
relevant chronic conditions. (5)
Local adverse effects (pain,
rash, induration) and systemic
adverse effects (malaise,
myalgia, headache) were
significantly more common after
the squalene adjuvant vaccine
than after other influenza
vaccines. Pharmacovigilance data
collected by the company show no
unexpected adverse events. (6)
In practice, there is no reason
to prefer the squalene adjuvant
vaccine to existing vaccines for
elderly people, whether or not
they have underlying chronic
conditions.
====================================================================
44.) Antibodies to squalene
in recipients of anthrax
vaccine.
====================================================================
Exp Mol Pathol. 2002
Aug;73(1):19-27.
Asa PB, Wilson RB, Garry RF.
Department of Microbiology,
Tulane University Medical
School, New Orleans, Louisiana
70112, USA.
We previously reported that
antibodies to squalene, an
experimental vaccine adjuvant,
are present in persons with
symptoms consistent with Gulf
War Syndrome (GWS) (P. B. Asa et
al., Exp. Mol. Pathol 68,
196-197, 2000). The United
States Department of Defense
initiated the Anthrax Vaccine
Immunization Program (AVIP) in
1997 to immunize 2.4 million
military personnel. Because
adverse reactions in vaccinated
personnel were similar to
symptoms of GWS, we tested AVIP
participants for anti-squalene
antibodies (ASA). In a pilot
study, 6 of 6 vaccine recipients
with GWS-like symptoms were
positive for ASA. In a larger
blinded study, only 32% (8/25)
of AVIP personnel compared to
15.7% (3/19) of controls were
positive (P > 0.05). Further
analysis revealed that ASA were
associated with specific lots of
vaccine. The incidence of ASA in
personnel in the blinded study
receiving these lots was 47%
(8/17) compared to an incidence
of 0% (0/8; P < 0.025) of the
AVIP participants receiving
other lots of vaccine. Analysis
of additional personnel revealed
that in all but one case (19/20;
95%), ASA were restricted to
personnel immunized with lots of
vaccine known to contain
squalene. Except for one
symptomatic individual, positive
clinical findings in 17
ASA-negative personnel were
restricted to 4 individuals
receiving vaccine from lots
containing squalene. ASA were
not present prior to vaccination
in preimmunization sera
available from 4 AVIP personnel.
Three of these individuals
became ASA positive after
vaccination. These results
suggest that the production of
ASA in GWS patients is linked to
the presence of squalene in
certain lots of anthrax vaccine.
=======================================================================
45.)Aluminum hydroxide
injections lead to motor
deficits and motor neuron
degeneration.
=======================================================================
J Inorg Biochem. 2009
Nov;103(11):1555-62. Epub 2009
Aug 20.
Shaw CA, Petrik MS.
Departments of Ophthalmology and
Visual Sciences, University of
British Columbia, Vancouver,
British Columbia, Canada.
[email protected]
Gulf War Syndrome is a
multi-system disorder afflicting
many veterans of Western armies
in the 1990-1991 Gulf War. A
number of those afflicted may
show neurological deficits
including various cognitive
dysfunctions and motor neuron
disease, the latter expression
virtually indistinguishable from
classical amyotrophic lateral
sclerosis (ALS) except for the
age of onset. This ALS "cluster"
represents the second such ALS
cluster described in the
literature to date. Possible
causes of GWS include several of
the adjuvants in the anthrax
vaccine and others. The most
likely culprit appears to be
aluminum hydroxide. In an
initial series of experiments,
we examined the potential
toxicity of aluminum hydroxide
in male, outbred CD-1 mice
injected subcutaneously in two
equivalent-to-human doses. After
sacrifice, spinal cord and motor
cortex samples were examined by
immunohistochemistry.
Aluminum-treated mice showed
significantly increased
apoptosis of motor neurons and
increases in reactive astrocytes
and microglial proliferation
within the spinal cord and
cortex. Morin stain detected the
presence of aluminum in the
cytoplasm of motor neurons with
some neurons also testing
positive for the presence of
hyper-phosphorylated tau
protein, a pathological hallmark
of various neurological
diseases, including Alzheimer's
disease and frontotemporal
dementia. A second series of
experiments was conducted on
mice injected with six doses of
aluminum hydroxide. Behavioural
analyses in these mice revealed
significant impairments in a
number of motor functions as
well as diminished spatial
memory capacity. The
demonstrated neurotoxicity of
aluminum hydroxide and its
relative ubiquity as an adjuvant
suggest that greater scrutiny by
the scientific community is
warranted.
=======================================================================
46.) Aluminum-induced model
of motor neuron degeneration:
subperineurial injection of
aluminum in rabbits.
=======================================================================
Neurotoxicology. 1995
Fall;16(3):413-24.\
Kihira T, Yoshida S, Komoto J,
Wakayama I, Yase Y.
Division of Neurological
Diseases, Wakayama Medical
College, Japan.
Environmental factors,
particularly chronic exposure to
aluminum (Al) and manganese (Mn)
with dietary deficiency of
calcium (Ca) and magnesium (Mg),
are speculated to be
contributory in the pathogenesis
of amyotrophic lateral sclerosis
(ALS). However, the mechanisms
by which these elements
accumulate in the CNS tissues
and induce neuronal death are
not known. In the present study,
we investigated the retrograde
transport of Al as a possible
mechanism of pathogenesis. Al
(as aluminum chloride or maltol)
was injected into the
subepineurial space of the
sciatic nerve with subsequent
morphological evaluation of the
neurotoxic effect on spinal
motor neurons in rabbits.
Spheroid/globules, central and
peripheral chromatolysis, and
neuronal degeneration were
observed in the spinal anterior
horn in Al-maltol, Al chloride,
and maltol treated rabbits to
more marked extent than those in
uninjected or saline controls.
By electron microscopy, the soma
and dendrites of neurons in the
anterior horn at the fifth
lumbar spinal cord in the
Al-treated rabbit showed marked
edematous change, fragmentation
of granular endoplasmic
reticulum, increased
accumulation of neurofilament,
and accumulation of free
ribosomes and lipid-droplet-like
structures. Horseradish
peroxidase (HRP) reactive
product was seen in the axons
and cytoplasm of Schwann cells
of the sciatic nerve in
Al-maltol treated rabbits,
suggesting that the permeability
of the blood-nerve-barrier was
increased by injection of
Al-maltol. We suggest that Al,
subperineurially injected, was
absorbed into the spinal cord
and induced degeneration of
spinal motor neurons in these
rabbits. These findings indicate
that the retrograde transport of
Al into spinal motor neurons via
the peripheral nervous system
may exacerbate neuronal
degeneration in ALS.
=========================================================
47.) Vaccines as a trigger
for myopathies.
==========================================================
Lupus. 2009 Nov;18(13):1213-6.
Orbach H, Tanay A.
Department of Medicine B,
Wolfson Medical Center, Holon,
Israel.
[email protected]
Vaccines are considered to be
among the greatest medical
discoveries, credited with the
virtual eradication of some
diseases and the consequent
improved survival and quality of
life of the at-risk population.
With that, vaccines are among
the environmental factors
implicated as triggers for the
development of inflammatory
myopathies. The sporadic reports
on vaccine-induced inflammatory
myopathies include cases of
hepatitis B virus, bacillus
Calmette-Guérin, tetanus,
influenza, smallpox, polio,
diphtheria,
diphtheria-pertussis-tetanus,
combination of diphtheria with
scarlet fever and
diphtheria-pertussis-tetanus
with polio vaccines. However, a
significant increase in the
incidence of dermatomyositis or
polymyositis after any massive
vaccination campaign has not
been reported in the literature.
In study patients with
inflammatory myopathies, no
recent immunization was recorded
in any of the patients.
Moreover, after the 1976 mass
flu vaccination, no increase in
the incidence of inflammatory
myopathies was observed.
Although rare, macrophagic
myofasciitis has been reported
following vaccination and is
attributed to the aluminium
hydroxide used as an adjuvant in
some vaccines. Prospective
multicenter studies are needed
to identify potential
environmental factors, including
vaccines, as potential triggers
for inflammatory myopathies.
===================================================================
48.) Induction of
metallothionein in mouse
cerebellum and cerebrum with
low-dose thimerosal injection.
====================================================================
Cell Biol Toxicol. 2009 Apr 9.
[Epub ahead of print]
Minami T, Miyata E, Sakamoto Y,
Yamazaki H, Ichida S.
Department of Life Sciences,
School of Science & Engineering,
Kinki University, 3-4-1
Kowakae, Higashi-osaka, Osaka,
577-8502, Japan,
[email protected].
Thimerosal, an ethyl mercury
compound, is used worldwide as a
vaccine preservative. We
previously observed that the
mercury concentration in mouse
brains did not increase with the
clinical dose of thimerosal
injection, but the concentration
increased in the brain after the
injection of thimerosal with
lipopolysaccharide, even if a
low dose of thimerosal was
administered. Thimerosal may
penetrate the brain, but is
undetectable when a clinical
dose of thimerosal is injected;
therefore, the induction of
metallothionein (MT) messenger
RNA (mRNA) and protein was
observed in the cerebellum and
cerebrum of mice after
thimerosal injection, as MT is
an inducible protein. MT-1 mRNA
was expressed at 6 and 9 h in
both the cerebrum and
cerebellum, but MT-1 mRNA
expression in the cerebellum was
three times higher than that in
the cerebrum after the injection
of 12 microg/kg thimerosal. MT-2
mRNA was not expressed until 24
h in both organs. MT-3 mRNA was
expressed in the cerebellum from
6 to 15 h after the injection,
but not in the cerebrum until 24
h. MT-1 and MT-3 mRNAs were
expressed in the cerebellum in a
dose-dependent manner.
Furthermore, MT-1 protein was
detected from 6 to 72 h in the
cerebellum after 12 microg/kg of
thimerosal was injected and
peaked at 10 h. MT-2 was
detected in the cerebellum only
at 10 h. In the cerebrum, little
MT-1 protein was detected at 10
and 24 h, and there were no
peaks of MT-2 protein in the
cerebrum. In conclusion, MT-1
and MT-3 mRNAs but not MT-2 mRNA
are easily expressed in the
cerebellum rather than in the
cerebrum by the injection of
low-dose thimerosal. It is
thought that the cerebellum is a
sensitive organ against
thimerosal. As a result of the
present findings, in combination
with the brain pathology
observed in patients diagnosed
with autism, the present study
helps to support the possible
biological plausibility for how
low-dose exposure to mercury
from thimerosal-containing
vaccines may be associated with
autism.
============================================================
49.) Neonate exposure to
thimerosal mercury from
hepatitis B vaccines.
=============================================================
Am J Perinatol. 2009
Aug;26(7):523-7. Epub 2009 Mar
12.=
Dórea JG, Marques RC, Brandão
KG.
Universidade de Brasília, DF,
Brazil. [email protected]
Infant exposure to ethylmercury
(EtHg) has not only increased
but is starting earlier as a
result of the current
immunization schedule that uses
thimerosal-containing vaccines
(TCVs). Although vaccination
schedule varies considerably
between countries, infants in
less-developed countries
continue to be exposed to EtHg
derived from more affordable
TCVs. We studied the exposure of
newborns to EtHg from hepatitis
B vaccines; hospital records
(21,685) were summarized for the
years 2001 to 2005 regarding
date of birth, vaccination date,
and birth weight. Most of the
vaccinations occurred in the
first 24 hours postdelivery;
over the 5 years, there was an
increase in vaccinations within
hours of birth (same day), from
7.4% (2001) to 87.8% (2005).
Nearly 94.6% of infants are now
being vaccinated within the
first 24 hours. Range of mercury
exposure spread from 4.2 to 21.1
microg mercury/kg body weight
for those receiving TCVs with
the highest thimerosal
concentration; these exposure
levels are conservative for 2%
of children receiving vaccines
within 2 to 3 postnatal days,
when they are still going
through physiological postnatal
weight loss. Because of the
particular timing (transitioning
from in utero to ex utero
metabolism) and specific aspects
of exposure (i.e., parenteral
mode, bypassing gastroenteric
barriers) and dose (related to
vaccine manufacturer and with
variation in birth weight), this
study reveals critical issues
that can modulate toxicokinetics
and toxicodynamics of
organomercurials in neonates.
=================================================
50.) Secret CDC vaccine study
Thimerosal an autism risk
=================================================
Sources: www.whale.to
AUTISM FIRST STEPS
AUTISM DAILY NEWSLETTER
Thursday January 3, 2002
SPECIAL EDITION
An unreleased confidential
report by Center's for Disease
Control (CDC) scientists reveals
that
exposure to significant amounts
of mercury during the first
months of life significantly
increases a
child's risk of developing
autism, according to an attorney
with the law firm of Walters &
Kraus. The
firm is a part of a coalition of
law firms, representing families
in at least 25 states, that has
filed
lawsuits in an attempt to force
drug companies to investigate
the possible link between
mercury and developmental
disorders.
Attorney Andy Walters says that
the unreleased CDC report,
obtained by the SAFEMINDS
advocacy group, found a 2.48
times increased risk of autism
in children exposed to more then
62.5
micrograms of mercury before
they were 3 months of age. In a
press release, Walters and
Kraus
notes that "in the United
States, courts of law have
generally held that a relative
increased risk of 2.0 or higher
is sufficient to substantiate
that a given exposure causes
disease." Walters says that in
many of the cases that his firm
has evaluated, autistic children
have received more than 62.5
micrograms of mercury through
pediatric vaccines.
A report made public by the CDC
in the fall claimed that the
thimerosal, the mercury
containing
preservative used in many
vaccines, could not be linked to
autism, while calling on
Physicians to
avoid thimerosal containing
vaccines when possible. However,
according to Walters & Kraus,
the
confidential CDC report states:
"As for the exposure evaluated
at 3 months of age, we found
increasing risks of
"neurological developmental
disorders" with increasing
cumulative exposure to
thimerosal... within the group
of "developmental disorders"...
for the subgroup called
"specific
delays," and within the this
subgroup for the specific
disorder "developmental speech
disorder," and
for "autism" "stuttering" and
"attention deficit disorder".
Walters says the report's
contents, and the fact that it
was kept secret, are "shocking,
but
unfortunately not surprising,
given the political influence of
pharmaceutical companies and
the
tremendous liability they face
if they are forced to compensate
thousands of families for the
costs of
care that these children
require".
Press Release, Walters & Kraus,
2001
******************************
PRESS RELEASE
An announcement was made today
by the law firm of Waters &
Kraus, the firm that filed the
first
known lawsuit alleging that a
mercury preservative in
children's vaccines caused
neurological damage to an infant
ultimately diagnosed with
autism. Waters & Kraus is
leading a consortium of ten
firms in as many states that are
actively prosecuting cases of
this nature (firms listed
below). Andy Waters, the lead
attorney in the cases, announced
that his firm is now in
possession of a
previously unreleased
confidential report authored by
Centers for Disease Control
scientists which studied autism
as a potential neurological
injury caused by mercury in
children's vaccines. A different
version of the report was made
public and has been cited by the
recent Institute of Medicine
study as inconclusive on the
issue of whether the
mercury-based vaccine
preservative known as
Thimerosal has contributed to
cause a nationwide epidemic of
regressive autism and other
neurological disorders in small
children. The confidential
version of the study, however,
clearly demonstrated that
an exposure to more than 62.5
micrograms of mercury within the
first three months of life
significantly increased a
child's risk of developing
autism. Specifically, the study
found a 2.48 times
increased risk of autism _ that
is to say, children with the
exposure were more than twice as
likely to develop autism as
children not exposed. Click here
to view the full report. (27
pages formatted in TIFF) In the
United States, courts of law
have generally held that a
relative increased risk of 2.0
or higher is sufficient to
substantiate that a given
exposure causes disease. As but
one example, in the case of Cook
v. United States, 545 F.Supp.
306, at 308 (Northern District _
California 1982) the
Court stated that, "in a vaccine
case, a relative risk greater
than 2.0 establishes that there
is a greater than 50% chance
that the injury was caused by
the vaccine." Waters indicated
that, in many of the cases his
firm has evaluated, including
the case filed in a Texas state
court on behalf of the Counter
family, the affected child
received more than 62.5
micrograms of mercury through
pediatric vaccines in the first
three months of life. The
confidential report, which was
obtained by the SAFEMINDS
support and advocacy group,
states: "As for the exposure
evaluated at 3 months of age, we
found increasing
risks of 'neurological
developmental disorders' with
increasing cumulative exposure
to thimerosal ...
within the group of
'developmental disorders'... for
the sub_group called 'specific
delays,' and within this
sub_group for the specific
disorder 'developmental speech
disorder,' and for 'autism,'
'stuttering' and 'attention
deficit disorder.'" The report
also contained the graph
depicted below which
illustrated the report's
findings of a child's increasing
risk of developing the
neurological symptoms of
autism after receiving
increasing amounts of
thimerosal.Graph 3: Relative
risk 95 % CI of Autism
after different exposure levels
of thimerosal at 3 months of
age, NCK & GHCWaters pointed out
that the confidential study's
lead author, Thomas Verstraeten,
has since left the Centers for
Disease Control and is now
employed by GlaxoSmithKline, a
manufacturer of
thimerosal_containing vaccines
for many years that is a
defendant in numerous suits
pending nationwide. "We have
asked GlaxoSmithKline to provide
Mr. Verstraeten's deposition in
order to understand if conflict
of interest issues may have
played a role in the CDC's
decision to keep this report
confidential, and
specifically, their failure to
reveal it to the Institute of
Medicine."Waters called the
report's contents and the
fact that it was kept from the
public as "shocking, but
unfortunately not surprising,
given the political influence of
pharmaceutical companies and the
tremendous liability they face
if they are forced to compensate
thousands of families for the
costs of care that these
children require." Waters
added that "no amount of money
can give these children back the
potential that they were born
with, and no amount of money
will comfort the parents that
watched helplessly as their
children literally just slipped
away." The purpose of the
lawsuits his firm is currently
prosecuting, said Waters, is "to
bring
to the surface the truth on this
issue, a truth that government
agencies seem unwilling to
admit,
perhaps for fear that parents
will stop vaccinating their
children, and to force the
companies that profited from
this disastrous mistake to
shoulder the responsibility that
so many families now bear
on their own, often without even
the aid of health insurance
benefits." Media inquiries
should be directed to Melissa
Miles at 214-357-6244.Client
inquiries should be directed to
Victoria Gibson, toll-free at
1-866-829-7529, or to the firms
listed below.Other firms working
with Waters & Kraus to prosecute
individual cases involving
thimerosal exposure are:ANDERSON
& KRIGER,
APLC40925 County Center Drive,
Suite 210Temecula, California
92591Telephone:
909.296.5090DOGAN & WILKINSON726
Delmas AvenuePascagoula,
Mississippi
39567Telephone: 228.762.2272
DORAN & MURPHY, LLP1234 Delaware
AvenueBuffalo, New
York 14209Telephone:
716.884.2000EVERT & WEATHERSBY,
L.L.C.3405 Piedmont Road,
Suite 225Atlanta, Georgia
30305-1764Telephone :
404.233.8718HENDRICKSON &
LONG214
Capital StreetP.O. Box
11070Charleston, W. VA
25339Telephone:
304.346.5500JONES,
MARTIN, PARRIS, &TESSENER LAW
OFFICES, PLLC410 Glenwood Ave.,
Suite
200Raleigh, North Carolina
27603Telephone:
919.821.0005LEACH, SCHWARZ
&STRASSBERG11 Bala Ave.Bala
Cynwyd, Pennsylvania
19004Telephone:
610.668.7964MARTZELL &
BICKFORD338 Lafayette StreetNew
Orleans, Louisianna
70130Telephone: 504.581.90653555
College AvenueWISE & JULIAN,
PC3555 College
AvenueAlton, Illinois
62002Telephone: 618.462.2600
=======================================================
51.) Possible hidden hazards
of mass vaccination against new
influenza A/H1N1: have the
cardiovascular risks been
adequately weighed?
========================================================
Med Microbiol Immunol. 2009 Oct
23. [Epub ahead of print]
Bhakdi S, Lackner K, Doerr HW.
Institute of Medical
Microbiology and Hygiene,
University Medical Center,
Augustusplatz, 55101, Mainz,
Germany, [email protected].
Programs for vaccination against
the new influenza A/H1N1
targeting many hundred million
citizens in Europe and the USA
are to be launched in the fall
of this year. The USA is
planning to employ a
non-adjuvanted vaccine, whereas
European nations are opting for
inclusion of MF59, the adjuvant
contained in an alternative
seasonal flu vaccine, or the
related adjuvant AS03 that is
contained in a recently
developed H5N1 vaccine. We draw
attention to unappreciated
hazards of using adjuvanted
vaccine in Europe. Evidence from
animal experiments in
conjunction with clinical
epidemiological data indicates
that, quite irrespective of
cause, stimulation of the immune
system may accelerate
atherogenesis. Application of
adjuvanted flu vaccines to
individuals at risk may
therefore aggravate the course
of underlying atherosclerotic
vessel disease with all the
clinical consequences. The same
may hold true for other
widespread diseases that are
propelled by deregulated immune
mechanisms. Safety trials
conducted to date have not
specifically taken these
possible side effects into
account, and unexpected serious
adverse effects thus may follow
in the wake of a general
vaccination program. A prudent
consequence would be to
establish careful survey systems
alongside with mass application
of new adjuvanted vaccines, or
to hold mass vaccination in
reserve for use only in
situations of true need, such as
would arise with the emergence
of a more virulent new H1N1
virus strain, or to use
non-adjuvanted vaccines in
individuals who are potentially
at risk for adverse side
effects.
===============================================
52.) Adjuvants and
autoimmunity.
================================================
Lupus. 2009 Nov;18(13):1217-25
Israeli E, Agmon-Levin N, Blank
M, Shoenfeld Y.
Center for Autoimmune Diseases,
Sheba Medical Center,
Tel-Hashomer, Israel.
Some adjuvants may exert adverse
effects upon injection or, on
the other hand, may not trigger
a full immunological reaction.
The mechanisms underlying
adjuvant adverse effects are
under renewed scrutiny because
of the enormous implications for
vaccine development. In the
search for new and safer
adjuvants, several new adjuvants
were developed by pharmaceutical
companies utilizing new
immunological and chemical
innovations. The ability of the
immune system to recognize
molecules that are broadly
shared by pathogens is, in part,
due to the presence of special
immune receptors called
toll-like receptors (TLRs) that
are expressed on leukocyte
membranes. The very fact that
TLR activation leads to adaptive
immune responses to foreign
entities explains why so many
adjuvants used today in
vaccinations are developed to
mimic TLR ligands. Alongside
their supportive role, adjuvants
were found to inflict by
themselves an illness of
autoimmune nature, defined as
'the adjuvant diseases'. The
debatable question of silicone
as an adjuvant and connective
tissue diseases, as well as the
Gulf War syndrome and
macrophagic myofaciitis which
followed multiple injections of
aluminium-based vaccines, are
presented here. Owing to the
adverse effects exerted by
adjuvants, there is no doubt
that safer adjuvants need to be
developed and incorporated into
future vaccines. Other needs in
light of new vaccine
technologies are adjuvants
suitable for use with mucosally
delivered vaccines, DNA
vaccines, cancer and
autoimmunity vaccines. In
particular, there is demand for
safe and non-toxic adjuvants
able to stimulate cellular (Th1)
immunity. More adjuvants were
approved to date besides alum
for human vaccines, including
MF59 in some viral vaccines,
MPL, AS04, AS01B and AS02A
against viral and parasitic
infections, virosomes for HBV,
HPV and HAV, and cholera toxin
for cholera. Perhaps future
adjuvants occupying other
putative receptors will be
employed to bypass the TLR
signaling pathway completely in
order to circumvent common side
effects of adjuvant-activated
TLRs such as local inflammation
and the general malaise felt
because of the costly whole-body
immune response to antigen.
====================================================================
53.)Oseltamivir-Resistant
Influenza Virus A (H1N1),
Europe, 2007–08 Season
===================================================================
Adam Meijer, Angie Lackenby,
Olav Hungnes, Bruno Lina, Sylvie
van der Werf, Brunhilde
Schweiger, Matthias Opp, John
Paget, Jan van de Kassteele,
Alan Hay, Maria Zambon, and on
behalf of the European Influenza
Surveillance Scheme1
Netherlands Institute for Health
Services Research, Utrecht, the
Netherlands (A. Meijer, J.
Paget)
National Institute for Public
Health and the Environment,
Bilthoven, the Netherlands (A.
Meijer,
J. van de Kassteele)
European Surveillance Network
for Vigilance against Viral
Resistance (A. Lackenby, B.
Lina, S. van der Werf, A. Hay,
M. Zambon)
Health Protection Agency,
London, UK (A. Lackenby, M.
Zambon)
Norwegian Institute of Public
Health, Oslo, Norway (O.
Hungnes); Centre National de
Référence des Virus Influenza
(Région Sud), Lyon, France (B.
Lina)
Centre National de Référence des
Virus Influenza (Région Nord),
Paris, France (S. van der Werf)
Robert Koch Institute, Berlin,
Germany (B. Schweiger)
Laboratoire National de Santé,
Luxembourg, Luxembourg (M. Opp)
World Health Organization
Collaborating Centre Medical
Research Council/National
Institute of Medical Research,
London (A. Hay)
Corresponding author.
Address for correspondence: Adam
Meijer, Centre for Infectious
Disease Control, National
Institute for Public Health and
the Environment, PO Box 1, 3720
BA Bilthoven, the Netherlands;
email: [email protected]
This article has been cited by
other articles in PMC.
Abstract
In Europe, the 2007–08 winter
season was dominated by
influenza virus A (H1N1)
circulation through week 7,
followed by influenza B virus
from week 8 onward.
Oseltamivir-resistant influenza
viruses A (H1N1) (ORVs) with
H275Y mutation in the
neuraminidase emerged
independently of drug use. By
country, the proportion of ORVs
ranged from 0% to 68%, with the
highest proportion in Norway.
The average weighted prevalence
of ORVs across Europe increased
gradually over time, from near 0
in week 40 of 2007 to 56% in
week 19 of 2008 (mean 20%).
Neuraminidase genes of ORVs
possessing the H275Y
substitution formed a
homogeneous subgroup closely
related to, but distinguishable
from, those of
oseltamivir-sensitive influenza
viruses A (H1N1). Minor variants
of ORVs emerged independently,
indicating multiclonal ORVs.
Overall, the clinical effect of
ORVs in Europe, measured by
influenza-like illness or acute
respiratory infection, was
unremarkable and consistent with
normal seasonal activity.
==============================================================
54.) Oseltamivir-Resistant
Influenza Viruses A (H1N1),
Norway, 2007–08
===============================================================
Siri H. Hauge, Susanne Dudman,
Katrine Borgen, Angie Lackenby,
and Olav Hungnes
Norwegian Institute of Public
Health, Oslo, Norway (S.H.
Hauge, S. Dudman, K. Borgen, O.
Hungnes)
Health Protection Agency,
London, UK (A. Lackenby)
Corresponding author.
Address for correspondence: Olav
Hungnes, Norwegian Institute of
Public Health, Department of
Virology, PO Box 4404, Nydalen
Oslo N-0403, Norway; email:
[email protected]
Abstract
In Norway in January 2008,
unprecedented levels of
oseltamivir resistance were
found in 12 of 16 influenza
viruses A (H1N1) tested. To
investigate the epidemiologic
and clinical characteristics of
these viruses, we used sequence
analysis to test all available
subtype H1N1 viruses from the
2007–08 season for resistance.
Questionnaires from physicians
provided information on
predisposing diseases,
oseltamivir use, symptoms, and
complications. Clinical data
were obtained for 265 patients.
In total, 183 (67.3%) of 272
viruses were oseltamivir
resistant. Resistance was not
associated with prior use of
antiviral drugs. Symptoms and
hospitalization rates did not
differ for patients infected
with a resistant or a
susceptible virus.
Oseltamivir-resistant influenza
viruses A (H1N1) did not show
diminished capability to spread
in the absence of selective
pressure. The ability of these
viruses to sustain their fitness
and spread among persons should
be considered when shaping
future strategies for treating
and preventing seasonal and
pandemic influenza.
==================================================================
DATA-MEDICOS/DERMAGIC-EXPRESS No 19-(208) 10/09/2.017 DR. JOSE LAPENTA R.
===================================================================
Produced
by Dr. Jose Lapenta R. Dermatologist 2.017
Maracay Estado Aragua Venezuela 2.017
Telf: 0416-6401045- 02432327287-02432328571
loading...
|